Human Microbiome Market (4th Edition), 2022-2035
The human microbiome remained a largely unexplored area until 2007 when the Human Microbiome Project (HMP) was initiated. The project was undertaken to understand the concept of core human microbiome and its compatibility with the host physiology. Further, with the significant advancements in the sequencing methods and analytical techniques, and 40% increase in the non-HMP investments, several microbiome-related studies have been conducted. Research insights generated from the HMP and other studies throw light on the role of gut microbiota in governing the overall health / well-being of an individual, and the pathogenesis of several diseases due to the alteration in the composition of resident gut microbiota. Specifically, the studies suggest that dysbiosis (imbalance of gut bacteria) leads to the development of several chronic conditions, including Clostridium difficile infections (CDIs), Crohn’s disease, irritable bowel disease, ulcerative colitis and diabetes. Given the role of microbiota in disease development and pathogenesis, the concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, thereby, defining a new frontier in the field of medicine. Manipulation of bacteria in the gut emerges to be a potential tool in the treatment of various medical conditions and associated diseases. The ongoing research efforts, focused on targeting and modulating microbiome, have led to the development of treatment options for more than 25 indications. In addition, probiotic therapies with live biotherapeutic products (microbes) are considered to be the most advanced microbiome-based therapies for restoring bacterial symbiosis.
At present, fecal microbiota transplantation (FMT) involving the transfer of complete microbial community from a healthy donor’s feces to recipient via oral (in form of a capsule) or rectal (enema and colonoscopy) is the only FDA-approved microbiome therapy, for the treatment of recurrent CDI. However, several players are engaged in developing prescription drugs modulating human microbiome for the treatment of various gastrointestinal and non-gastrointestinal disorders as well. Further, a number of microbiome diagnostic and screening / profiling tests are commercially available for the detection of different microbiome-related diseases. It is worth mentioning that, owing to the rising interest, a number of start-ups / small firms have established in the past few years and the contributions of big pharma players have fueled the overall growth in this domain. Driven by increasing prevalence of disease indications, promising therapeutic potential of microbiome-based therapies, encouraging clinical trial results and financial support from the investors, the human microbiome therapeutics and diagnostics market is likely to witness substantial growth in the mid to long-term.
SCOPE OF THE REPORT
The ‘The Human Microbiome Market (4th Edition), 2022-2035: Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapies: Distribution by Type of Molecule (Small Molecule and Biologic), Type of Product (Probiotic Drugs and Other Drugs), Target Indication (Bacterial Vaginosis, Diabetes, Gingivitis, Irritable Bowel Syndrome, Leaky Gut Syndrome, Graft Versus Host Disease, Necrotizing Enterocolitis, Primary Hyperoxaluria, recurrent CDI, Trichomoniasis and Vaginal Candidiasis), Therapeutic Areas (Dental Disorders, Digestive and Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, Rare Disorders and Others)Route of Administration (Oral and Rectal), Supply Channels (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) and Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of microbiome-based medical products (including therapeutics, diagnostics and FMTs), over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:
The opinions and insights presented in this study were also influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company / organization names):
Human Microbiome Market (4th Edition): Market Segmentations
Market Segments Details
Forecast Period
Type of Molecule
RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This information is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
KEY QUESTIONS ANSWERED
Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the current state and likely evolution of microbiome therapeutics, diagnostics and FMT therapies market in the short-mid term and long term.
Chapter 3 provides a general overview of human microbiome, concepts pertaining to microbiota and microbiome, a discussion on the role of resident microorganisms in disease development (particularly for conditions caused by an imbalance in the microbiome) and in certain cases, prevention. It presents an elaborate assessment on various functions of the microbiota, emphasizing on the key aspects of the Human Microbiome Project (HMP). Further, the chapter describes the various types of microbiome therapeutics, such as probiotics and prebiotic drugs, which are available / under development. It also provides an overview of the regulatory requirements for live biotherapeutic products (LBPs), in addition to highlighting the challenges associated with the development of microbiome therapeutics.
Chapter 4 includes detailed assessment of the current market landscape of microbiome therapeutics, providing information on preclinical and clinical drugs along with information on clinical study sponsor(s) or collaborators, phase of development (clinical, preclinical, and discovery) of product candidates, type of molecule (small molecule and biologic), type of therapy (prebiotic, probiotic, prescription drug and vaccine), target indication(s), therapeutic area(s), route of administration, type of drug formulation, type of therapy (monotherapy and combination therapy), combination drug (in case of combination therapies), dosing frequency (reported for clinical candidates only), and special drug designations (if any). In addition, the chapter provides details on the companies engaged in the development of microbiome therapeutics, along with information on their year of establishment, company size and location of headquarters.
Chapter 5 features detailed profiles of key players engaged in the development of microbiome therapeutics (which are presently in phase III clinical trials); each profile features a brief overview of the company, its financial information (if available), microbiome-based drug portfolio, information on clinical trial (featuring, current status of development and phase III clinical trial information) and an informed future outlook. In addition, the chapter also features profiles of the players engaged in more than six therapeutic programs, along with a company overview, financial information (if available), drug portfolio and an informed future outlook.
Chapter 6 features an analysis of completed and ongoing clinical trials of various microbiome therapeutics, based on different parameters, such as trial status, trial registration year, trial status year-wise trend of completed and recruiting trials, study design, number of patients enrolled. In addition, the chapter highlights, the age group of the patients enrolled, type of sponsor / collaborator, active industry and non-industry players and location of the trials.
Chapter 7 features an analysis on various types of diagnostic and screening / profiling tests, specifically highlighting the importance of next-generation sequencing within this field of research, along with detailed review of the current market landscape of microbiome diagnostic and screening / profiling tests, including the information on stage of development (commercialized and under development), type of sample analyzed (blood, feces, saliva and vaginal swab), type of screening technique (gene sequencing, PCR, microarray, ELISA, DNA analysis, drug metabolites and others) target indication(s), key therapeutic area(s) and purpose of diagnosis. The chapter also features information on the diagnostics and screening / profiling test providers(s) along with information on their year of establishment, company size and location of headquarters.
Chapter 8 presents elaborate profiles of key players engaged in the development of microbiome diagnostics and screening / profiling tests. Each profile features a brief overview of the company, its financial information (if available), diagnostic or screening / profiling test portfolio, recent developments and an informed future outlook.
Chapter 9 presents review of the historical evolution and other relevant aspects of FMT, including details on the process of donor selection, therapy procedure, route of administration, important clinical guidelines, regulatory guidelines and insurance coverage, along with detailed assessment of the current market landscape of FMT, providing information on various parameters of FMT such as, the status of development (commercialized, clinical, and preclinical stage), target indication(s), key therapeutic area(s), and route of administration. In addition, the chapter includes information on FMT provider(s), along with information on their year of establishment, company size and location of headquarters.
Chapter 10 highlights a detailed analysis of completed and ongoing clinical trials of FMT, based on different parameters, such as trial status, trial registration year, trial phase, year-wise trend of completed and recruiting trials, study design, number of patients enrolled. In addition, the chapter highlights, age category of the patients enrolled, type of sponsor / collaborator, active industry and non-industry players and location of the trials. Furthermore, the chapter also features information on various stool banks (including year of establishment and location of headquarters), along with brief profiles of the most prominent stool banks located across the globe.
Chapter 11 features an insightful business portfolio analysis based on an attractiveness and competitiveness (AC) framework, highlighting the current market attractiveness and existing competition across the most popular disease indication(s) for which microbiome therapeutics are under investigation.
Chapter 12 highlights an analysis of the varied microbiome-focused initiatives of big pharma players (out of top 20 established pharmaceutical players), featuring a heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome product developers), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and a spider web representation of the individual competitiveness of the initiatives of big pharma players based on multiple relevant parameters.
Chapter 13 presents the detailed analysis of the start-ups / small-sized players (established in the last seven years, with less than 50 employees) engaged in the development of microbiome therapeutics and diagnostics, featuring heat map representation based on parameters, such as number of microbiome therapeutics under development, diversity of product portfolio, funding information (including funding amount, number of investors and evolution of investment activity), partnership activity, disease indication(s) being treated and focus therapeutic area(s).
Chapter 14 presents an assessment of the most commonly targeted therapeutic indications and details of microbiome-based drugs that are being developed against them, highlighting key epidemiological facts about specific diseases, available methods of diagnosis, and currently available treatment options and their side effects.
Chapter 15 presents analysis of the partnerships that have been established since 2017, covering various parameters such as, research and development, clinical trials agreement, merger / acquisition, product development and commercialization agreement and product development and manufacturing agreement of the companies focused on developing microbiome-based therapeutics, diagnostics and FMTs.
Chapter 16 presents a detailed analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in start-ups / small-sized companies (with less than 50 employees) that are focused on developing microbiome therapeutics and diagnostics.
Chapter 17 features an elaborate discussion on the various steps involved in the development and manufacturing of microbiome therapeutics, along with an indicative list of contract manufacturers, along with details on year of establishment, location of headquarters, company size, scale of operation, type of product manufactured and type of formulation. In addition, the chapter highlights key consideration for selecting a CMO / CRO partner.
Chapter 18 presents an assessment of the emerging role of big data, highlighting efforts focused on the development and implementation of various algorithms / tools to analyze data generated from microbiome research along with insightful google trends analysis to demonstrate the rising interest of stakeholders in using big data tools to support microbiome research over the past decade. The chapter also features a list of companies offering big data-related services / tools to support microbiome research, and brief profiles of some of the popular companies that are engaged in this field of research.
Chapter 19 features an elaborate market forecast analysis, highlighting the future potential of microbiome therapeutics till 2035. Based on an informed top-down approach, taking into account current and projected performance of the microbiome therapeutics market, it features the likely distribution of the current and forecasted opportunity across type of molecule (small molecule and biologics), type of product (probiotic and other drugs), target indication (graft versus host disease, necrotizing enterocolitis, primary hyperoxaluria and recurrent CDI), therapeutic area (digestive and gastrointestinal disorders, infectious diseases and rare disorders), route of administration (oral and rectal), key geographical regions (North America, Europe, Asia-Pacific and rest of the world), leading drug developers, and leading therapeutic products. The potential sales forecast of the therapeutic products that are in the later stages of development (phase III) is based on multiple relevant parameters, such as target consumer segments, region-specific disease prevalence, anticipated adoption of the late-stage drugs and likely selling price.
Chapter 20 features a detailed market forecast analysis, highlighting the future potential of microbiome-based diagnostic tests till 2030. Based on multiple parameters, such as target consumer segments, disease prevalence, anticipated adoption of diagnostic tests and price, the analysis provides an informed opinion on the likely distribution of the current and forecasted opportunity across target indication (bacterial vaginosis, diabetes, gingivitis, irritable bowel syndrome, leaky gut syndrome, trichomoniasis and vaginal candidiasis), therapeutic area (digestive and gastrointestinal disorders, metabolic disorders and others), supply channel (hospital pharmacies, retail pharmacies, and online pharmacies), and key geographical regions (North America, Europe, Asia-Pacific and rest of the world). It is worth mentioning that a bottom-up approach was adopted for this analysis, wherein our estimates of the likely size of the microbiome-based diagnostics market were validated using relevant datapoints and inputs from primary research. The chapter features market projections both in terms of value (USD million) and volume (number of diagnostic tests).
Chapter 21 features an informed market forecast analysis, highlighting the future opportunity within the FMT market till 2035, based on parameters, such as the average number of FMT procedures conducted in a year and average cost of approved FMT. It is worth mentioning that the chapter features market projections both in terms of value (USD million) and volume (number of procedures).
Chapter 22 is a case study on various other applications of microbiome products, such as agriculture, animal health, plant health, food products, featuring a list of nearly 80 products, including probiotic supplements, cosmetics, and over the counter (OTC) products that are being used as dietary supplements.
Chapter 23 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinions related to the research and analysis described in the previous chapters.
Chapter 24 consists of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Lee Jones (President and Chief Executive Officer, Rebiotix), Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic), Colleen Cutcliffe (Co-founder and Chief Executive Officer, Pendulum Therapeutics), Nikole E Kimes (Co-founder and Chief Executive Officer, Siolta Therapeutics), James Burges (Co-founder and Vice President of Innovation, Finch Therapeutics), JP Benya (Vice President, Operation, Flame Biosciences), Debbie Pinkston (Former Vice President, Sales and Business Development, List Biological Laboratories), Gregory J Kuehn (Vice President, Business Development and Marketing, Metabiomics), Mark Heiman (Chief Scientific Officer and Vice President, Research, Scioto Biosciences), Alexander Segal (Founder, Stealth Startup), Assaf Oron (Chief Business Officer, BiomX), Pierre-Alain Bandinelli (Chief Strategy Officer, Da Volterra), Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical), Aaron Wright (Senior Scientist, Pacific Northwest National Laboratories), Nicholas Monsul (Co-founder and Chairman, Quorum Innovations) and Charlie Badham (Senior Manager, Corporate Development, 4D Pharma).
Chapter 25 is an appendix, that contains the tabulated data and numbers for all the figures in the report.
Chapter 26 is an appendix, that provides the list of companies and organizations mentioned in the report.
- 1. PREFACE
- 1.1. Scope of the Report
- 1.2. Research Methodology
- 1.3. Key Questions Answered
- 1.4. Chapter Outlines
- 2. EXECUTIVE SUMMARY
- 3. INTRODUCTION
- 3.1. Chapter Overview
- 3.2. Concept of Microbiota and Microbiome
- 3.2.1. Discovery of the Human Microbiome
- 3.2.2. Functions of the Human Microbiome
- 3.3. Overview of Gut Flora
- 3.3.1. Role of Gut Flora in Human Health
- 3.3.2. Factors Affecting Gut Flora
- 3.3.2.1. Antibiotic Consumption
- 3.3.2.2. Age and Pregnancy
- 3.3.2.2.1. Mode of Childbirth
- 3.3.2.2.2. Type of Feeding
- 3.3.2.2.3. Antibiotic Consumption by Mother
- 3.3.2.3. Stress-related Factors
- 3.3.2.4. Dietary Factors
- 3.3.2.5. Impact of Lifestyle
- 3.4. The Microbiome and Associated Diseases
- 3.4.1. Cancer
- 3.4.2. Inflammatory Bowel Disease (IBD)
- 3.4.3. Obesity
- 3.4.4. Parkinson’s Disease
- 3.4.5. Type 2 Diabetes
- 3.4.6. Other Disease Indications
- 3.5. Impact of Microbiota on Drug Pharmacokinetics
- 3.6. Impact of Microbiota on Therapeutic Outcomes
- 3.7. Microbiome Therapeutics
- 3.7.1. Probiotics
- 3.7.1.1. Beneficial Bacterial Strains
- 3.7.1.1.1. Lactobacilli
- 3.7.1.1.2. Bifidobacteria
- 3.7.1.1.3. Others
- 3.7.1.2. Key Therapeutic Areas
- 3.7.1.2.1. Antibiotic-Associated Diarrhea (AAD)
- 3.7.1.2.2. Bacterial Vaginosis
- 3.7.1.2.3. High Blood Pressure
- 3.7.1.2.4. Hypercholesterolemia
- 3.7.1.2.5. Infectious Childhood Diarrhea (ICD)
- 3.7.1.2.6. Inflammatory Bowel Disease (IBD)
- 3.7.1.2.7. Lactose Intolerance
- 3.7.1.2.8. Vitamin Production
- 3.7.1.2.9. Weight Management
- 3.7.1.3. Side Effects of Probiotics
- 3.7.2. Prebiotics
- 3.7.2.1. Sources of Prebiotics
- 3.7.2.2. Types of Prebiotics
- 3.7.2.2.1. Fructo-Oligosaccharides (FOS)
- 3.7.2.2.2. Galacto-Oligosaccharides (GOS)
- 3.7.2.2.3. Inulin
- 3.7.2.3. Key Therapeutic Areas
- 3.7.2.3.1. Antibiotic Associated Diarrhea (AAD)
- 3.7.2.3.2. Constipation
- 3.7.2.3.3. Gastrointestinal Diseases
- 3.7.2.3.4. Dysbiosis
- 3.7.2.4. Side Effects of Prebiotics
- 3.8. The Human Microbiome Project (HMP)
- 3.8.1. Project Approach
- 3.8.2. Project Initiatives
- 3.8.3. Project Achievements
- 3.9. Regulatory Guidelines for Live Biotherapeutic Products (LBPs)
- 3.10. Key Challenges Associated with the Development of Microbiome Therapeutics
- 3.11. Future Perspectives
- 4. MICROBIOME THERAPEUTICS: MARKET LANDSCAPE
- 4.1. Chapter Overview
- 4.2. Microbiome Therapeutics: Clinical Pipeline
- 4.2.1. Analysis by Phase of Development
- 4.2.2. Analysis by Type of Molecule
- 4.2.3. Analysis by Phase of Development and Type of Molecule
- 4.2.4. Analysis by Type of Biologic
- 4.2.5. Analysis by Type of Product
- 4.2.6. Analysis by Target Indication
- 4.2.7. Analysis by Therapeutic Area
- 4.2.8. Analysis by Route of Administration
- 4.2.9. Analysis by Type of Formulation
- 4.2.10. Analysis by Dose Frequency
- 4.2.11. Analysis by Type of Therapy
- 4.2.12. Analysis by Combination Drug
- 4.3. Microbiome Therapeutics: Preclinical Pipeline
- 4.3.1. Analysis by Phase of Development
- 4.3.2. Analysis by Type of Molecule
- 4.3.3. Analysis by Phase of Development and Type of Molecule
- 4.3.4. Analysis by Type of Biologic
- 4.3.5. Analysis by Type of Product
- 4.3.6. Analysis by Target Indication
- 4.3.7. Analysis by Therapeutic Area
- 4.3.8. Analysis by Route of Administration
- 4.4. Microbiome Therapeutics: List of Drug Developers
- 4.4.1. Analysis by Year of Establishment
- 4.4.2. Analysis by Company Size
- 4.4.3. Analysis by Location of Headquarters
- 4.4.4. Analysis by Company Size and Location of Headquarters
- 4.4.5. Leading Drug Developers: Analysis by Number of Therapeutic Programs
- 5. MICROBIOME THERAPEUTICS: COMPANY AND DRUG PROFILES
- 5.1. Chapter Overview
- 5.2. Microbiome Therapeutics Developers: Companies with Candidate(s) in Highest Phase of Development
- 5.3. Finch Therapeutics
- 5.3.1. Company Overview
- 5.3.2. Microbiome-Based Product Portfolio
- 5.3.2.1. CP101
- 5.3.2.1.1. Drug Overview
- 5.3.2.1.2. Current Status of Development
- 5.3.2.1.3. Clinical Studies
- 5.3.3. Recent Developments and Future Outlook
- 5.4. Infant Bacterial Therapeutics
- 5.4.1. Company Overview
- 5.4.2. Microbiome-Based Product Portfolio
- 5.4.2.1. IBP-9414
- 5.4.2.1.1. Drug Overview
- 5.4.2.1.2. Current Status of Development
- 5.4.2.1.3. Clinical Studies
- 5.4.3. Recent Developments and Future Outlook
- 5.5. MaaT Pharma
- 5.5.1. Company Overview
- 5.5.2. Microbiome-Based Product Portfolio
- 5.5.2.1. MaaT013
- 5.5.2.1.1. Drug Overview
- 5.5.2.1.2. Current Status of Development
- 5.5.2.1.3. Clinical Studies
- 5.5.3. Recent Developments and Future Outlook
- 5.6.1 OxThera
- 5.6.1. Company Overview
- 5.6.2. Microbiome-Based Product Portfolio
- 5.6.2.1. Oxabact
- 5.6.2.1.1. Drug Overview
- 5.6.2.1.2. Current Status of Development
- 5.6.2.1.3. Clinical Studies
- 5.6.3. Recent Developments and Future Outlook
- 5.7. Rebiotix (acquired by Ferring Pharmaceuticals)
- 5.7.1. Company Overview
- 5.7.2. Financial Information
- 5.7.3. Microbiome-Based Product Portfolio
- 5.7.3.1. RBX2660
- 5.7.3.1.1. Drug Overview
- 5.7.3.1.2. Current Status of Development
- 5.7.3.1.3. Clinical Studies
- 5.7.4. Recent Developments and Future Outlook
- 5.8. Seres Therapeutics
- 5.8.1. Company Overview
- 5.8.2. Financial Information
- 5.8.3. Microbiome-Based Product Portfolio
- 5.8.3.1. SER-109
- 5.8.3.1.1. Drug Overview
- 5.8.3.1.2. Current Status of Development
- 5.8.3.1.3. Clinical Studies
- 5.8.3.1.4. Clinical Trial End-Point Analysis
- 5.9. Microbiome Therapeutics Developers: Companies with Maximum Number of Therapeutic Programs
- 5.10. 4D Pharma
- 5.10.1. Company Overview
- 5.10.2. Financial Information
- 5.10.3. Microbiome-based Drug Portfolio
- 5.10.4. Recent Developments and Future Outlook
- 5.11. Biosortia Pharmaceuticals
- 5.11.1. Company Overview
- 5.11.2 Microbiome-based Drug Portfolio
- 5.11.3. Recent Developments and Future Outlook
- 5.12. Qu Biologics
- 5.12.1. Company Overview
- 5.12.2. Microbiome-based Drug Portfolio
- 5.12.3. Recent Developments and Future Outlook
- 5.13. Servatus
- 5.13.1 Company Overview
- 5.13.2. Microbiome-based Drug Portfolio
- 5.13.3. Recent Developments and Future Outlook
- 6. CLINICAL TRIAL ANALYSIS: HUMAN MICROBIOME THERAPEUTICS
- 6.1. Chapter Overview
- 6.2. Human Microbiome Therapeutics: List of Clinical Trials
- 6.2.1. Analysis by Trial Status
- 6.2.2. Analysis by Trial Registration Year
- 6.2.3. Analysis by Trial Registration Year and Type of Study
- 6.2.4. Analysis by Trial Phase and Trial Status
- 6.2.5. Year-wise Trend of Completed and Recruiting Trials
- 6.2.6. Analysis by Study Design
- 6.2.7. Analysis by Patient Enrollment
- 6.2.8. Analysis by Age Category
- 6.2.9. Analysis by Type of Sponsor / Collaborator
- 6.2.10. Most Active Industry Players: Analysis by Number of Registered Trials
- 6.2.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
- 6.2.12. Analysis by Trial Location
- 6.2.13. Analysis by Trial Status and Geography
- 7. MICROBIOME DIAGNOSTICS AND SCREENING / PROFILING TESTS: MARKET LANDSCAPE
- 7.1. Chapter Overview
- 7.2. Overview of Microbiome Diagnostics and Screening / Profiling Tests
- 7.3. Microbiome Diagnostics and Screening / Profiling Tests: Marketed and Under Development Products
- 7.3.1. Analysis by Stage of Development
- 7.3.2. Analysis by Type of Test
- 7.3.3. Analysis by Stage of Development and Type of Test
- 7.3.4. Analysis by Type of Sample Analyzed
- 7.3.5. Analysis by Type of Screening Technique
- 7.3.6. Analysis by Target Indication
- 7.3.7. Analysis by Therapeutic Area
- 7.3.8. Analysis by Purpose of Test
- 7.4. Microbiome Diagnostic and Screening / Profiling Tests Providers
- 7.4.1. Analysis by Year of Establishment
- 7.4.2. Analysis by Company Size
- 7.4.3. Analysis by Location of Headquarters
- 7.4.4. Analysis by Company Size and Location of Headquarters
- 7.4.5. Most Active Microbiome Test Providers: Analysis by Number of Microbiome Tests
- 8. MICROBIOME DIAGNOSTIC AND SCREENING / PROFILING TEST PROVIDERS: COMPANY PROFILES
- 8.1. Chapter Overview
- 8.2. Shoreline Biome
- 8.2.1. Company Overview
- 8.2.2. Microbiome Test Portfolio
- 8.2.3. Recent Developments and Future Outlook
- 8.3. DNA Genotek
- 8.3.1. Company Overview
- 8.3.2. Microbiome Test Portfolio
- 8.3.3. Recent Developments and Future Outlook
- 8.4. Invivo Healthcare
- 8.4.1. Company Overview
- 8.4.2. Microbiome Test Portfolio
- 8.4.3. Recent Developments and Future Outlook
- 8.5. GoodGut
- 8.5.1. Company Overview
- 8.5.2. Microbiome Test Portfolio
- 8.5.3. Recent Developments and Future Outlook
- 8.6. BiomeDx
- 8.6.1. Company Overview
- 8.6.2. Microbiome Test Portfolio
- 8.6.3. Recent Developments and Future Outlook
- 9. FECAL MICROBIOTA THERAPY (FMT)
- 9.1. Chapter Overview
- 9.2. Introduction to Fecal Microbiota Therapy
- 9.3. Historical Overview
- 9.4. Fecal Microbiota Therapy: Procedure and Clinical Relevance
- 9.4.1. Donor Selection
- 9.4.2. Administration Procedure
- 9.4.3. Routes of Administration
- 9.4.4. Consequences and Adverse Events
- 9.4.5. Clinical Guidelines Associated with Fecal Microbiota Therapy
- 9.5. Regulatory Guidelines Related to Fecal Microbiota Therapy
- 9.6. Insurance Coverage for Fecal Microbota Therapy
- 9.7. Fecal Microbiota Therapy: Marketed and Development Pipeline
- 9.7.1. Analysis by Application Area
- 9.7.2. Analysis by Status of Development
- 9.7.3. Analysis by Target Indication
- 9.7.1.2. Analysis by Therapeutic Area
- 9.7.1.3. Analysis by Route of Administration
- 9.8. Fecal Microbiota Therapy: List of Developers
- 9.8.1. Analysis by Year of Establishment
- 9.8.2. Analysis by Company Size
- 9.8.3. Analysis by Location of Headquarters
- 9.9. Stool Banks
- 9.9.1. Introduction to Stool Banks
- 9.9.2. List of Stool Banks
- 9.9.3. Profiles of Prominent Stool Banks
- 9.9.3.1. AdvancingBio
- 9.9.3.1.1. Overview
- 9.9.3.1.2. Fecal Microbiota Preparation
- 9.9.3.2. Asia Microbiota bank
- 9.9.3.2.1. Overview
- 9.9.3.2.2. Fecal Microbiota Preparation
- 9.9.3.3. Enterobiotix
- 9.9.3.3.1. Overview
- 9.9.3.3.2. Fecal Microbiota Preparation
- 9.9.3.4. Flora Medicine
- 9.9.3.4.1. Overview
- 9.9.3.4.2. Fecal Microbiota Preparation
- 9.9.3.5. OpenBiome
- 9.9.3.5.1. Overview
- 9.9.3.5.2. Fecal Microbiota Preparation
- 10. CLINICAL TRIALS ANALYSIS: FECAL MICROBIOTA THERAPY
- 10.1. Chapter Overview
- 10.2. List of Clinical Trials
- 10.2.1. Analysis by Trial Status
- 10.2.2. Analysis by Trial Registration Year
- 10.2.3. Analysis by Trial Registration Year and Type of Study
- 10.2.4. Analysis by Trial Phase and Trial Status
- 10.2.5. Year-wise Trend of Completed and Recruiting Trials
- 10.2.6. Analysis by Study Design
- 10.2.7. Analysis by Patient Enrollment
- 10.2.8. Analysis by Age Category
- 10.2.9. Analysis by Type of Sponsor / Collaborator
- 10.2.10. Most Active Industry Players: Analysis by Number of Registered Trials
- 10.2.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
- 10.2.12. Analysis by Trial Location
- 10.2.13. Analysis by Trial Status and Geography
- 11. ATTRACTIVENESS COMPETITIVENESS (AC) MATRIX
- 11.1. Chapter Overview
- 11.2. AC Matrix: An Overview
- 11.2.1. Strong Business Units
- 11.2.2. Average Business Units
- 11.2.3. Weak Business Units
- 11.3. AC Matrix: Analytical Methodology
- 11.4. AC Matrix: Plotting the Information
- 11.5. AC Matrix: Analyzing the Data
- 11.5.1. Strong Business Units
- 11.5.2. Average Business Units
- 11.5.3. Weak Business Units
- 11.6. Concluding Remarks
- 12. MICROBIOME RELATED INITIATIVES OF BIG PHARMA PLAYERS
- 12.1. Chapter Overview
- 12.2. Scope and Methodology
- 12.3. Initiatives of Big Pharma Players
- 12.3.1. Analysis by Portfolio Diversity
- 12.3.2. Analysis by Phase of Development
- 12.3.3. Analysis by Type of Molecule
- 12.3.4. Analysis by Type of Therapy
- 12.3.5. Analysis by Diversity of Therapeutic Areas
- 12.4. Benchmarking Analysis of Big Pharma Players
- 12.4.1. Spider Web Analysis: Company A
- 12.4.2. Spider Web Analysis: Company B
- 12.4.3. Spider Web Analysis: Company C
- 12.4.4. Spider Web Analysis: Company D
- 12.4.5. Spider Web Analysis: Company E
- 12.4.6. Spider Web Analysis: Company F
- 12.4.7. Spider Web Analysis: Company G
- 12.4.8. Spider Web Analysis: Company H
- 12.4.9. Spider Web Analysis: Company I
- 12.4.10. Spider Web Analysis: Company J
- 12.4.11. Spider Web Analysis: Company K
- 13. START-UP HEALTH INDEXING
- 13.1. Chapter Overview
- 13.2. Scope and Methodology
- 13.3. Benchmarking of Start-ups
- 13.3.1. Analysis by Portfolio Diversity
- 13.3.2. Analysis by Phase of Development
- 13.3.3. Analysis by Diversity in Therapeutic Areas
- 13.3.4. Analysis by Funding Amount
- 13.3.5. Analysis by Number of Investors
- 13.3.6. Analysis by Type of Funding
- 13.3.7. Analysis by Partnership Activity
- 13.3.8. Analysis by Patent Portfolio
- 13.3.9. Start-up Health Indexing: Roots Analysis Perspective
- 14. KEY THERAPEUTIC AREAS
- 14.1. Chapter Overview
- 14.2. Metabolic Disorders
- 14.2.1. Diabetes
- 14.2.1.1. Disease Description
- 14.2.1.2. Associated Health Risks / Complications
- 14.2.1.3. Epidemiology
- 14.2.1.4. Disease Diagnosis
- 14.2.1.5. Current Treatment Options
- 14.2.1.5.1. Insulin Therapies
- 14.2.1.5.2. Non-Insulin Therapies
- 14.2.1.6. Side Effects of Current Treatment Options
- 14.2.1.7. Microbiome Therapeutics for Diabetes
- 14.2.2. Lactose Intolerance
- 14.2.2.1. Disease Description
- 14.2.2.2. Epidemiology
- 14.2.2.3. Current Treatment Options
- 14.2.2.4. Microbiome Therapeutics for Lactose Intolerance
- 14.2.3. Nonalcoholic Steatohepatitis (NASH)
- 14.2.3.1. Disease Description
- 14.2.3.2. Epidemiology
- 14.2.3.3. Current Treatment Options
- 14.2.3.4. Microbiome Therapeutics for NASH
- 14.2.4. Primary Hyperoxaluria
- 14.2.4.1. Disease Description
- 14.2.4.2. Epidemiology
- 14.2.4.3. Current Treatment Options
- 14.2.4.4. Microbiome Therapeutics for Primary Hyperoxaluria
- 14.2.5. Obesity
- 14.2.5.1. Disease Description
- 14.2.5.2. Epidemiology
- 14.2.5.3. Current Treatment Options
- 14.2.5.4. Side Effects of Current Treatment Options
- 14.2.5.5. Microbiome Therapeutics for Obesity
- 14.3. Digestive and Gastrointestinal Disorders
- 14.3.1. Crohn’s Disease
- 14.3.1.1. Disease Description
- 14.3.1.2. Epidemiology
- 14.3.1.3. Current Treatment Options
- 14.3.1.4. Side Effects of Current Treatment Options
- 14.3.1.5. Microbiome Therapeutics for Crohn’s Disease
- 14.3.2. Irritable Bowel Syndrome (IBS)
- 14.3.2.1. Disease Description
- 14.3.2.2. Epidemiology
- 14.3.2.3. Current Treatment Options
- 14.3.2.4. Microbiome Therapeutics for IBS
- 14.3.3. Ulcerative Colitis
- 14.3.3.1. Disease Description
- 14.3.3.2. Epidemiology
- 14.3.3.3. Current Treatment Options
- 14.3.3.4. Side Effects of Current Treatment Options
- 14.3.3.5. Microbiome Therapeutics for Ulcerative Colitis
- 14.4. Oncological Indications
- 14.4.1. Colorectal Cancer
- 14.4.1.1. Disease Description
- 14.4.1.2. Epidemiology
- 14.4.1.3. Current Treatment Options
- 14.4.1.4. Side Effects of Current Treatments
- 14.4.1.5. Microbiome Therapeutics for Colorectal Cancer
- 14.4.2. Lung Cancer
- 14.4.2.1. Disease Description
- 14.4.2.2. Epidemiology
- 14.4.2.3. Current Treatment Options
- 14.4.2.4. Side Effects of Current Treatment Options
- 14.4.2.5. Microbiome Therapeutics for Lung Cancer
- 14.5. Dermatological Disorders
- 14.5.1. Acne Vulgaris
- 14.5.1.1. Disease Description
- 14.5.1.2. Epidemiology
- 14.5.1.3. Current Treatment Options
- 14.5.1.4. Side Effects of Current Treatment Options
- 14.5.1.5. Microbiome Therapeutics for Acne Vulgaris
- 14.6. Infectious Diseases
- 14.6.1. Clostridium Difficile Infections (CDIs)
- 14.6.1.1. Disease Description
- 14.6.1.2. Epidemiology
- 14.6.1.3. Disease Diagnosis
- 14.6.1.4. Current Treatment Options
- 14.6.1.5. Side Effects of Current Treatment Options
- 14.6.1.6. Microbiome Therapeutics for CDI
- 14.6.2. Bacterial Vaginosis
- 14.6.2.1. Disease Description
- 14.6.2.2. Epidemiology
- 14.6.2.3. Current Treatment Options
- 14.6.2.4. Side Effects of Current Treatment Options
- 14.6.2.5. Microbiome Therapeutics for Bacterial Vaginosis
- 15. PARTNERSHIPS AND COLLABORATIONS
- 15.1. Chapter Overview
- 15.2. Partnership Models
- 15.3. Human Microbiome: List of Partnerships and Collaborations
- 15.4. Analysis by Year of Partnership
- 15.5. Analysis by Type of Partnership
- 15.6. Analysis by Year and Type of Partnership
- 15.7. Analysis by Type of Product
- 15.8. Analysis by Target Indication
- 15.9. Analysis by Therapeutic Area
- 15.10. Analysis by Type of Company
- 15.11. Analysis by Type of Partner
- 15.12. Most Active Players: Analysis by Number of Partnerships
- 15.13. Intercontinental and Intracontinental Agreements
- 16. FUNDING AND INVESTMENT ANALYSIS
- 16.1. Chapter Overview
- 16.2. Types of Funding
- 16.3. Microbiome Therapeutics and Diagnostics: List of Funding and Investments
- 16.3.1. Analysis by Year of Investment
- 16.3.2. Analysis by Amount Invested
- 16.3.3. Analysis by Type of Funding
- 16.3.4. Analysis by Type of Company
- 16.3.5. Analysis by Purpose of Funding
- 16.3.6. Analysis by Type of Product
- 16.3.7. Analysis by Target Indication
- 16.3.9. Analysis by Therapeutic Area
- 16.3.10. Analysis by Geography
- 16.3.11. Most Active Players: Analysis by Number of Instances
- 16.3.12. Most Active Players: Analysis by Amount Invested
- 16.3.12. Most Active Investors: Analysis by Number of Instances
- 16.3.13 Funding and Investment Summary
- 17. CASE STUDY: CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS AND LIVE BIOTHERAPEUTICS
- 17.1. Chapter Overview
- 17.2. Manufacturing Microbiome Therapeutics
- 17.2.1. Key Steps Involved
- 17.2.2. Associated Challenges
- 17.2.3. Growing Demand for Contract Manufacturing Services
- 17.2.4. Contract Manufacturing Organizations (CMOs)
- 17.2.4.1. Introduction to Contract Manufacturing
- 17.2.5. Microbiome Therapeutics: List of Contract Manufacturing Providers
- 17.2.5.1. Analysis by Year of Establishment
- 17.2.5.2. Analysis by Company Size
- 17.2.5.3. Analysis by Location of Headquarters
- 17.2.5.4. Analysis by Scale of Operation
- 17.2.5.5. Analysis by Type of Product Manufactured
- 17.2.5.6. Analysis by Type of Formulation
- 17.2.5.7. Analysis by Scale of Operation and Type of Formulation
- 17.3. Key Considerations for Selecting a CMO / CRO Partner
- 18. BIG DATA AND MICROBIOME THERAPEUTICS
- 18.1. Chapter Overview
- 18.2. Introduction to Big Data
- 18.3. Internet of Things (IoT)
- 18.4. Growing Interest in Big Data: Google Trends Analysis
- 18.5. Key Application Areas
- 18.6. Big Data in Microbiome Research
- 18.6.1. Microbiome Data and Personalized Medicine
- 18.6.2. Microbiome-related Data Management Challenges
- 18.6.3. National Microbiome Data Center
- 18.7. Big Data Services for Microbiome Research: List of Companies
- 18.8. Big Data Services for Microbiome Research: Profiles of Key Players
- 18.8.1. Human Longevity
- 18.8.1.1. Company Overview
- 18.8.1.2. Technology and Service Portfolio
- 18.8.1.3. Recent Developments and Future Outlook
- 18.8.2. Resilient Biotics
- 18.8.2.1. Company Overview
- 18.8.2.2. Technology and Service Portfolio
- 18.8.2.3. Recent Developments and Future Outlook
- 18.8.3. Resphera Biosciences
- 18.8.3.1. Company Overview
- 18.8.3.2. Technology and Service Portfolio
- 18.8.3.3. Recent Developments and Future Outlook
- 19. MICROBIOME THERAPEUTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS
- 19.1. Chapter Overview
- 19.2. Key Assumptions
- 19.3. Forecast Methodology
- 19.4. Global Microbiome Therapeutics Market, 2022-2035
- 19.4.1. Microbiome Therapeutics Market: Distribution by Type of Product 2022-2035
- 19.4.1.1. Microbiome Therapeutics Market for Probiotic Drugs, 2022-2035
- 19.4.1.2. Microbiome Therapeutics Market for Other Drugs, 2022-2035
- 19.4.2. Microbiome Therapeutics Market: Distribution by Type of Molecule, 2022-2035
- 19.4.2.1. Microbiome Therapeutics Market for Small Molecules, 2022-2035
- 19.4.2.2. Microbiome Therapeutics Market for Biologics, 2022-2035
- 19.4.3. Microbiome Therapeutics Market: Distribution by Target Disease Indication, 2022-2035
- 19.4.3.1. Microbiome Therapeutics Market for Graft Versus Host Disease, 2022-2035
- 19.4.3.2. Microbiome Therapeutics Market for Necrotizing Enterocolitis, 2022-2035
- 19.4.3.3. Microbiome Therapeutics Market for Primary Hyperoxaluria, 2022-2035
- 19.4.3.4. Microbiome Therapeutics Market for Recurrent C. difficile Infection, 2022-2035
- 19.4.4. Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2022-2035
- 19.4.4.3. Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, 2022-2035
- 19.4.4.1. Microbiome Therapeutics Market for Infectious Diseases, 2022-2035
- 19.4.4.2. Microbiome Therapeutics Market for Rare Disorders, 2022-2035
- 19.4.5. Microbiome Therapeutics Market: Route of Administration, 2022-2035
- 19.4.5.1. Microbiome Therapeutics Market for Oral Therapeutics, 2022-2035
- 19.4.5.2. Microbiome Therapeutics Market for Rectal Therapeutics, 2022-2035
- 19.4.6. Microbiome Therapeutics Market: Distribution by Key Geographical Regions, 2022-2035
- 19.4.6.1. Microbiome Therapeutics Market in North America, 2022-2035
- 19.4.6.2. Microbiome Therapeutics Market in Europe, 2022-2035
- 19.4.6.3. Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, 2022-2035
- 19.4.7. Microbiome Therapeutics Market: Distribution by Leading Drug Developers, 2022-2035
- 19.5. Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, 2022-2035
- 19.5.1. Drug-wise Sales Forecast
- 19.5.1.1. CP101 (Finch Therapeutics)
- 19.5.1.2. Sales Forecast, 2022-2035 (USD Million)
- 19.5.1.3. Net Present Value (USD Million)
- 19.5.1.4. Value Creation Analysis
- 19.5.2.1. IBP-9414 (Infant Bacterial Therapeutics)
- 19.5.2.2. Sales Forecast, 2022-2035 (USD Million)
- 19.5.2.3. Net Present Value (USD Million)
- 19.5.2.4. Value Creation Analysis
- 19.5.2.1. MaaT013 (MaaT Pharma)
- 19.5.2.2. Sales Forecast,2022-2035 (USD Million)
- 19.5.2.3. Net Present Value (USD Million)
- 19.5.2.4. Value Creation Analysis
- 19.5.2.1. Oxabact (OxThera)
- 19.5.2.2. Sales Forecast, 2022-2035 (USD Million)
- 19.5.2.3. Net Present Value (USD Million)
- 19.5.2.4. Value Creation Analysis
- 19.5.2.1. RBX2660 (Rebiotix)
- 19.5.2.2. Sales Forecast, 2022-2035 (USD Million)
- 19.5.2.3. Net Present Value (USD Million)
- 19.5.2.4. Value Creation Analysis
- 19.5.4.1. SER-109 (Seres Therapeutics)
- 19.5.4.2. Sales Forecast (USD Million)
- 19.5.4.3. Net Present Value (USD Million)
- 19.5.4.4. Value Creation Analysis
- 20. MICROBIOME DIAGNOSTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS
- 20.1. Chapter Overview
- 20.2. Key Assumptions
- 20.3 Forecast Methodology
- 20.4. Global Microbiome Diagnostics Market, 2022-2035
- 20.4.1. Global Microbiome Diagnostics Market, 2022-2035 (By Value)
- 20.4.2. Global Microbiome Diagnostics Market, 2022-2035 (By Volume)
- 20.5. Microbiome Diagnostics Market: Distribution by Target Indication, 2022-2035
- 20.5.1. Microbiome Diagnostics Market: Distribution by Target Indication, 2022-2035 (By Value)
- 20.5.1.1. Microbiome Diagnostics Market for Crohn’s Disease, 2022-2035 (By Value)
- 20.5.1.2. Microbiome Diagnostics Market for Colorectal Cancer, 2022-2035 (By Value)
- 20.5.1.3. Microbiome Diagnostics Market for Diabetes, 2022-2035 (By Value)
- 20.5.1.4. Microbiome Diagnostics Market for IBS, 2022-2035 (By Value)
- 20.5.1.5. Microbiome Diagnostics Market for Lung Cancer, 2022-2035 (By Value)
- 20.5.1.6. Microbiome Diagnostics Market for NASH, 2022-2035 (By Value)
- 20.5.1.7. Microbiome Diagnostics Market for Obesity, 2022-2035 (By Value)
- 20.5.1.8. Microbiome Diagnostics Market for Ulcerative Colitis, 2022-2035 (By Value)
- 20.5.2. Microbiome Diagnostics Market: Distribution by Target Indication, 2022-2035 (By Volume)
- 20.5.2.1. Microbiome Diagnostics Market for Crohn’s Disease, 2022-2035 (By Volume)
- 20.5.2.2. Microbiome Diagnostics Market for Colorectal Cancer, 2022-2035 (By Volume)
- 20.5.2.3. Microbiome Diagnostics Market for Diabetes, 2022-2035 (By Volume)
- 20.5.2.4. Microbiome Diagnostics Market for IBS, 2022-2035 (By Volume)
- 20.5.2.5. Microbiome Diagnostics Market for Lung Cancer, 2022-2035 (By Volume)
- 20.5.2.6. Microbiome Diagnostics Market for NASH, 2022-2035 (By Volume)
- 20.5.2.7. Microbiome Diagnostics Market for Obesity, 2022-2035 (By Volume)
- 20.5.2.8. Microbiome Diagnostics Market for Ulcerative Colitis, 2022-2035 (By Volume)
- 20.6. Microbiome Diagnostics Market: Distribution by Therapeutic Area, 2022-2035
- 20.6.1. Microbiome Diagnostics Market: Distribution by Therapeutic Area, 2022-2035 (By Value)
- 20.6.1.2. Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2022-2035 (By Value)
- 20.6.1.2. Microbiome Diagnostics Market for Metabolic Disorders, 2022-2035 (By Value)
- 20.6.1.3. Microbiome Diagnostics Market for Oncology, 2022-2035 (By Value)
- 20.6.2. Microbiome Diagnostics Market: Distribution by Therapeutic Area, 2022-2035 (By Volume)
- 20.6.2.1. Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2022-2035 (By Volume)
- 20.6.2.2. Microbiome Diagnostics Market for Metabolic Disorders, 2022-2035 (By Volume)
- 20.6.2.3. Microbiome Diagnostics Market for Oncology, 2022-2035 (By Volume)
- 20.7. Microbiome Diagnostics Market: Distribution by Supply Channel, 2022-2035
- 20.7.1. Microbiome Diagnostics Market: Distribution by Supply Channel, 2022-2035 (By Value)
- 20.7.1.1. Microbiome Diagnostics Market for Hospital Pharmacies, 2022-2035 (By Value)
- 20.7.1.2. Microbiome Diagnostics Market for Retail Pharmacies, 2022-2035 (By Value)
- 20.7.1.3. Microbiome Diagnostics Market for Online Pharmacies, 2022-2035 (By Value)
- 20.7.2. Microbiome Diagnostics Market: Distribution by Supply Channel, 2022-2035 (By Volume)
- 20.7.2.1. Microbiome Diagnostics Market for Hospital Pharmacies, 2022-2035 (By Volume)
- 20.7.2.2. Microbiome Diagnostics Market for Retail Pharmacies, 2022-2035 (By Volume)
- 20.7.2.3. Microbiome Diagnostics Market for Online Pharmacies, 2022-2035 (By Volume)
- 20.8. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2022-2035
- 20.8.1. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2022-2035 (By Value)
- 20.8.1.1. Microbiome Diagnostics Market in North America, 2022-2035 (By Value)
- 20.8.1.2. Microbiome Diagnostics Market in Europe, 2022-2035 (By Value)
- 20.8.1.3. Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2022-2035 (By Value)
- 20.8.2. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2022-2035 (By Volume)
- 20.8.2.1. Microbiome Diagnostics Market in North America, 2022-2035 (By Volume)
- 20.8.2.2. Microbiome Diagnostics Market in Europe, 2022-2035 (By Volume)
- 20.8.2.3. Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2022-2035 (By Volume)
- 21. FECAL MICROBIOTA THERAPIES: MARKET FORECAST AND OPPORTUNITY ANALYSIS
- 21.1. Chapter Overview
- 21.2. Key Assumptions
- 21.3. Forecast Methodology
- 21.4. Overall FMT Market, 2022-2035
- 21.4.1. Overall FMT Market, 2022-2035 (By Value)
- 21.4.2. Overall FMT Market, 2022-2035 (By Volume)
- 21.5. Overall Microbiome Market by Product Offerings, 2022-2035
- 22. CASE STUDY: MICROBIOME-BASED PRODUCTS IN NON-PHARMACEUTICAL INDUSTRIES
- 22.1. Chapter Overview
- 22.2. List of Microbiome Products in Non-Pharmaceutical Industry
- 22.2.1. Applications of Microbiome Based Products in Cosmetics and Food Industry
- 22.3. Applications of Microbiome Based Products in Agriculture Industry
- 22.4. Future Perspectives
- 23. CONCLUDING REMARKS
- 24. EXECUTIVE INSIGHTS
- 24.1 Chapter Overview
- 24.2. Rebiotix
- 24.2.1. Company / Organization Snapshot
- 24.2.2. Interview Transcript: Lee Jones, President and Chief Executive Officer
- 24.3. S-Biomedic
- 24.3.1. Company / Organization Snapshot
- 24.3.2. Interview Transcript: Veronika Oudova, Co-founder and Chief Executive Officer
- 24.4. Pendulum Therpaeutics
- 24.4.1. Company / Organization Snapshot
- 24.4.2. Interview Transcript: Colleen Cutcliffe, Co-founder and Chief Executive Officer
- 24.5. Siolta Therapeutics
- 24.5.1. Company / Organization Snapshot
- 24.5.2. Interview Transcript: Nikole E Kimes, Founder and Vice President
- 24.6. Finch Therapeutics
- 24.6.1. Company / Organization Snapshot
- 24.6.2. Interview Transcript: James Burges, Co-Founder and Vice President of Innovation
- 24.7 Flame Biociences
- 24.7.1. Company / Organization Snapshot
- 24.7.2. Interview Transcript: JP Benya, Vice President, Business Development
- 24.8. List Biological Laboratories
- 24.8.1. Company / Organization Snapshot
- 24.8.2. Interview Transcript: Debbie Pinkston, Former Vice President, Sales and Business Development
- 24.9. Metabiomics
- 24.9.1. Company / Organization Snapshot
- 24.9.2. Interview Transcript: Gregory J Kuehn, President and Chief Operating Officer
- 24.10. Scioto Biosciences
- 24.10.1. Company / Organization Snapshot
- 24.10.2. Interview Transcript: Mark Heiman, Chief Scientific Officer and Vice President, Research
- 24.11. Stealth Startup
- 24.11.1. Company / Organization Snapshot
- 24.11.2. Interview Transcript: Alexander Segal, Founder
- 24.12. BiomX
- 24.12.1. Company / Organization Snapshot
- 24.12.2. Interview Transcript: Assaf Oron, Chief Business Officer
- 24.13. Da Volterra
- 24.13.1. Company / Organization Snapshot
- 24.13.2. Interview Transcript: Pierre-Alain Bandinelli, Chief Business Strategy Officer
- 24.14. Chung Mei Pharmaceutical
- 24.14.1. Company / Organization Snapshot
- 24.14.2. Interview Transcript: Alexander Lin, Associate General Manager
- 24.15. Pacific Northwest National Laboratories
- 24.15.1. Company / Organization Snapshot
- 24.15.2. Interview Transcript: Aaron Wright, Senior Scientist
- 24.16. Quorum Innovations
- 24.16.1. Company / Organization Snapshot
- 24.16.2. Interview Transcript: Nicholas T. Monsul, Co-founder and Chairman
- 24.17. 4D Pharma
- 24.17.1. Company / Organization Snapshot
- 24.17.2. Interview Transcript: Charlie Badham, Senior Manager, Corporate Development
- 25. APPENDIX I: TABULATED DATA
- 26. APPENDIX II:
- LIST OF COMPANIES AND ORGANIZATIONS
- LIST OF FIGURES
- Figure 3.1 Benefits of the Human Microbiota
- Figure 3.2 Factors Affecting Gut Microbiota
- Figure 3.3 Factors Affecting Gut Microbiota in Infants
- Figure 3.4 Impact of Diet on Gut Microbiota
- Figure 3.5 Types of Microbiome-Based Therapeutics
- Figure 3.6 Approaches to Design Microbiome Therapeutics
- Figure 3.7 Health Benefits of Probiotics
- Figure 3.8 Mechanism of Action of Probiotics
- Figure 3.9 Beneficial Bacterial Strains for Probiotics
- Figure 3.10 Key Achievements of the Human Microbiome Project (HMP)
- Figure 3.11 Challenges Associated with the Development of Microbiome Therapeutics
- Figure 4.1 Clinical Phase Microbiome Therapeutics: Distribution by Phase of Development
- Figure 4.2 Clinical Phase Microbiome Therapeutics: Distribution by Type of Molecule
- Figure 4.3. Clinical Phase Microbiome Therapeutics: Distribution by Phase of Development and Type of Molecule
- Figure 4.4 Clinical Phase Microbiome Therapeutics: Distribution by Type of Biologic
- Figure 4.5 Clinical Phase Microbiome Therapeutics: Distribution by Type of Product
- Figure 4.6 Clinical Phase Microbiome Therapeutics: Distribution by Target Indication
- Figure 4.7 Clinical Phase Microbiome Therapeutics: Distribution by Therapeutic Area
- Figure 4.8 Clinical Phase Microbiome Therapeutics: Distribution by Route of Administration
- Figure 4.9 Clinical Phase Microbiome Therapeutics: Distribution by Type of Formulation
- Figure 4.10 Clinical Phase Microbiome Therapeutics: Distribution by Dose Frequency
- Figure 4.11 Clinical Phase Microbiome Therapeutics: Distribution by Type of Therapy
- Figure 4.12 Clinical Phase Microbiome Therapeutics: Distribution by Combination Drug
- Figure 4.13 Preclinical Phase Microbiome Therapeutics: Distribution by Phase of Development
- Figure 4.14 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Molecule
- Figure 4.15. Preclinical Phase Microbiome Therapeutics: Distribution by Phase of Development and Type of Molecule
- Figure 4.11 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Biologic
- Figure 4.11 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Product
- Figure 4.12 Preclinical Phase Microbiome Therapeutics: Distribution by Target Indication
- Figure 4.13 Preclinical Phase Microbiome Therapeutics: Distribution by Therapeutic Area
- Figure 4.13 Preclinical Phase Microbiome Therapeutics: Distribution by Route of Administration
- Figure 4.14 Microbiome Therapeutic Developers: Distribution by Year of Establishment
- Figure 4.15 Microbiome Therapeutic Developers: Distribution by Company Size
- Figure 4.16 Microbiome Therapeutic Developers: Distribution by Location of Headquarters
- Figure 4.17 Microbiome Therapeutic Developers: Distribution by Company Size and Location of Headquarters
- Figure 4.18 Leading Drug Developers: Distribution by Number of Therapeutic Programs
- Figure 5.1 Rebiotix: Financial Information, 2017-2021 (USD Million)
- Figure 5.2 Seres Therapeutics: Financial Information, 2017-2021 (USD Million)
- Figure 5.3 4D Pharma: Financial Information, 2017-2021 (USD Million)
- Figure 6.1 Distribution by Trial Status
- Figure 6.2 Distribution by Trial Registration Year
- Figure 6.3 Distribution by Trial Registration Year and Type of Study
- Figure 6.4 Distribution by Trial Phase and Trial Status
- Figure 6.5 Year-wise Trend of Completed and Recruiting Trials
- Figure 6.6 Distribution by Study Design
- Figure 6.7 Distribution by Patient Enrollment
- Figure 6.8 Distribution by Age Category
- Figure 6.9 Distribution by Type of Sponsor / Collaborator
- Figure 6.10 Most Active Industry Players: Distribution by Number of Registered Trials
- Figure 6.11 Most Active Non-Industry Players: Distribution by Number of Registered Trials
- Figure 6.12 Distribution by Trial Location
- Figure 6.13 Distribution by Trial Status and Geography
- Figure 7.1 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Stage of Development
- Figure 7.2 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Test
- Figure 7.3 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Stage of Development and Type of Test
- Figure 7.4 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Sample Analyzed
- Figure 7.5 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Screening Technique
- Figure 7.6 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Target Indication
- Figure 7.7 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Therapeutic Area
- Figure 7.8 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Purpose of Test
- Figure 7.9 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Year of Establishment
- Figure 7.10 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Company Size
- Figure 7.11 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Location of Headquarters
- Figure 7.12 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Company Size and Location of Headquarters
- Figure 7.13 Most Active Microbiome Test Providers: Distribution by Number of Microbiome Tests
- Figure 9.1 Working Mechanism of a Microflora Refinement System
- Figure 9.2 Fecal Microbiota Transplantation: Distribution by Application Area
- Figure 9.3 Fecal Microbiota Transplantation: Distribution by Status of Development
- Figure 9.4 Fecal Microbiota Transplantation: Distribution by Target Indication
- Figure 9.5 Fecal Microbiota Transplantation: Distribution by Therapeutic Area
- Figure 9.6 Fecal Microbiota Transplantation: Distribution by Route of Administration
- Figure 9.7 Fecal Microbiota Transplantation Developers: Distribution by Year of Establishment
- Figure 9.8 Fecal Microbiota Transplantation Developers: Distribution by Company Size
- Figure 9.9 Fecal Microbiota Transplantation Developers: Distribution by Location of Headquarters
- Fgure 10.1 Fecal Microbiota Transplantation: Distribution by Trial Status
- Figure 10.2 Fecal Microbiota Transplantation: Distribution by Trial Registration Year
- Figure 10.3 Fecal Microbiota Transplantation: Distribution by Trial Registration Year and Type of Study
- Figure 10.4 Fecal Microbiota Transplantation: Distribution by Trial Phase and Trial Status
- Figure 10.5 Fecal Microbiota Transplantation: Year-wise Trend of Completed and Recruiting Trials
- Figure 10.6 Fecal Microbiota Transplantation: Distribution by Study Design
- Figure 10.7 Fecal Microbiota Transplantation: Distribution by Patient Enrollment
- Figure 10.8 Fecal Microbiota Transplantation: Distribution by Age Category
- Figure 10.9 Fecal Microbiota Transplantation: Distribution by Type of Sponsor / Collaborator
- Figure 10.10 Most Active Industry Players: Distribution by Number of Registered Trials
- Figure 10.11 Most Active Non-Industry Players: Distribution by Number of Registered Trials
- Figure 10.12 Fecal Microbiota Transplantation: Distribution by Trial Location
- Figure 10.13 Fecal Microbiota Transplantation: Distribution by Trial Status and Geography
- Figure 11.1 AC Matrix: Pictorial Representation
- Figure 11.2 AC Matrix: Positioning of Different Indications
- Figure 12.1 Heat Map Representation: Disttibution of Top Big Pharma Players
- Figure 12.2 Big Pharma Players: Analysis by Portfolio Diversity
- Figure 12.3 Big Pharma Players: Distribution by Phase of Development
- Figure 12.4 Big Pharma Players: Distribution by Type of Molecule
- Figure 12.5 Big Pharma Players: Distribution by Type of Therapy
- Figure 12.6 Big Pharma Players: Distribution by Diversity of Therapeutic Areas
- Figure 12.7 Spider Web Analysis: Company A
- Figure 12.8 Spider Web Analysis: Company B
- Figure 12.9 Spider Web Analysis: Company C
- Figure 12.10 Spider Web Analysis: Company D
- Figure 12.11 Spider Web Analysis: Company E
- Figure 12.12 Spider Web Analysis: Company F
- Figure 12.13 Spider Web Analysis: Company G
- Figure 12.14 Spider Web Analysis: Company H
- Figure 12.15 Spider Web Analysis: Company I
- Figure 12.16 Spider Web Analysis: Company J
- Figure 12.17 Spider Web Analysis: Company K
- Figure 13.1 Benchmarking of Start-ups: Distribution by Portfolio Diversity
- Figure 13.2 Benchmarking of Start-ups: Distribution by Phase of Development
- Figure 13.3 Benchmarking of Start-ups: Distribution by Diversity in Therapeutic Areas
- Figure 13.4 Benchmarking of Start-ups: Distribution by Funding Amount
- Figure 13.5 Benchmarking of Start-ups: Distribution by Number of Investors
- Figure 13.6 Benchmarking of Start-ups: Distribution by Type of Funding
- Figure 13.7 Benchmarking of Start-ups: Distribution by Partnership Activity
- Figure 13.8 Benchmarking of Start-ups: Distribution by Patent Portfolio
- Figure 13.9 Start-up Health Indexing: Roots Analysis Perspective
- Figure 14.1 Diabetes: Diagnostic Limits for Plasma Glucose Levels
- Figure 14.2 Non-Insulin Therapies for Diabetes
- Figure 14.3 Weight Categories as per BMI Calculations
- Figure 14.4 Causes of Obesity in Children
- Figure 14.5 Obese Population: Distribution by Key Regions
- Figure 15.1 Funding and Investment Analysis: Cumulative Distribution by Year of Investment, 2017-2022
- Figure 15.3 Funding and Investment Analysis: Distribution by Type of Funding and Year of Investment, 2017-2022
- Figure 15.4 Funding and Investment Analysis: Cumulative Distribution by Amount Invested, 2017-2022 (USD Million)
- Figure 15.5 Funding and Investment Analysis: Year-Wise Distribution by Amount Invested and Type of Funding, 2017-2022 (USD Million)
- Figure 15.6 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2017-2022
- Figure 15.7 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2017-2022 (USD Million)
- Figure 15.8 Funding and Investment Analysis: Summary of Amount Invested, 2017-2022 (USD Million)
- Figure 15.9 Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Company, 2017-2022 (USD Million)
- Figure 15.10 Funding and Investment Analysis: Distribution of the Total Amount Invested by Purpose of Funding, 2017-2022 (USD Million)
- Figure 15.11 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Product, 2017-2022 (USD Million)
- Figure 15.12 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Product and Funding Type, 2017-2022 (USD Million)
- Figure 15.13 Funding and Investment Analysis: Distribution by Target Indication
- Figure 15.14 Funding and Investment Analysis: Distribution of the Total Amount Invested by Target Indication, 2017-2022 (USD Million)
- Figure 15.15 Funding and Investment Analysis: Distribution by Therapeutic Area
- Figure 15.16 Funding and Investment Analysis: Distribution of the Total Amount Invested by Therapeutic Area, 2017-2022 (USD Million)
- Figure 15.17 Funding and Investment Analysis: Distribution by Geography
- Figure 15.18 Funding and Investment Analysis: Regional Distribution of Funding Instances
- Figure 15.19 Most Active Players: Distribution by Number of Instances and Amount Invested, 2017-2022 (USD Million)
- Figure 15.20 Most Active Investors: Distribution by Number of Instances
- Figure 15.21 Funding and Investment Summary, 2017-2022 (USD Million)
- Figure 16.1 Partnerships and Collaborations: Distribution of Year of Partnership
- Figure 16.2 Partnerships and Collaborations: Distribution of Type of Partnership
- Figure 16.3 Partnerships and Collaborations: Distribution of Year and Type of Partnership
- Figure 16.4 Partnerships and Collaborations: Distribution of Type of Product
- Figure 16.5 Partnerships and Collaborations: Distribution of Target Indication
- Figure 16.6 Partnerships and Collaborations: Distribution of Therapeutic Area
- Figure 16.7 Partnerships and Collaborations: Distribution of Type of Company
- Figure 16.8 Partnerships and Collaborations: Distribution of Type of Partner
- Figure 16.9 Most Active Players: Distribution by Number of Partnerships
- Figure 16.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
- Figure 17.1 Microbiome Therapeutics Manufacturing Process
- Figure 17.2 Challenges Associated with the Manufacturing of Microbiome
- Therapeutics
- Figure 17.3 Strategies to Optimize Microbiome Therapeutic Manufacturing Operations
- Figure 17.4 Microbiome Contract Manufacturers: Distribution by Year of Establishment
- Figure 17.5 Microbiome Contract Manufacturers: Distribution by Company Size
- Figure 17.6 Microbiome Contract Manufacturers: Distribution by Location of Headquarters
- Figure 17.7 Microbiome Contract Manufacturers: Distribution by Scale of Operation
- Figure 17.8 Microbiome Contract Manufacturers: Distribution by Type of Product Manufactured
- Figure 17.9 Microbiome Contract Manufacturers: Distribution by Type of Formulation
- Figure 17.10 Microbiome Contract Manufacturers: Distribution by Scale of Operation and Type of Formulation
- Figure 18.1 Big Data: The Three V’s
- Figure 18.2 Internet of Things: Framework
- Figure 18.3 Internet of Things: Applications in Healthcare
- Figure 18.4 Big Data: Google Trends
- Figure 18.4 Big Data and Microbiome: Google Trends
- Figure 18.5 Big Data: Key Application Areas
- Figure 18.6 Big Data: Opportunities in Healthcare
- Figure 18.7 Big Data: Key Benefits for Pharmaceutical and Biotechnology Products
- Figure 18.8 Challenges Associated with Microbiome-related Big Data Management
- Figure 19.1 Microbiome Therapeutics Market: Forecast Methodology and Key Assumptions
- Figure 19.2 Global Microbiome Therapeutics Market, 2022-2035 (USD Billion)
- Figure 19.3 Microbiome Therapeutics Market: Distribution by Type of Product, 2022 and 2035
- Figure 19.4 Microbiome Therapeutics Market for Probiotic Drugs, 2022-2035 (USD Million)
- Figure 19.5 Microbiome Therapeutics Market for Other Drugs, 2022-2035 (USD Million)
- Figure 19.7 Microbiome Therapeutics Market: Distribution by Type of Molecule, 2022 and 2035
- Figure 19.8 Microbiome Therapeutics Market for Small Molecules, 2022-2035 (USD Million)
- Figure 19.9 Microbiome Therapeutics Market for Biologics, 2022-2035 (USD Million)
- Figure 19.10 Microbiome Therapeutics Market: Distribution by Target Disease Indication, 2022 and 2035
- Figure 19.11 Microbiome Therapeutics Market for Graft Versus Host Disease, 2022-2035 (USD Million)
- Figure 19.12 Microbiome Therapeutics Market for Necrotizing Enterocolitis, 2022-2035 (USD Million)
- Figure 19.13 Microbiome Therapeutics Market for Primary Hyperoxaluria, 2022-2035 (USD Million)
- Figure 19.14 Microbiome Therapeutics Market for Recurrent C. difficile Infection, 2022-2035 (USD Million)
- Figure 19.15 Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2022 and 2035
- Figure 19.16 Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, 2022-2035 (USD Million)
- Figure 19.17 Microbiome Therapeutics Market for Infectious Diseases, 2022-2035 (USD Million)
- Figure 19.18 Microbiome Therapeutics Market for Rare Disorders, 2022-2035 (USD Million)
- Figure 119.19 Microbiome Therapeutics Market: Route of Administration, 2022-2035 (USD Million)
- Figure 19.20 Microbiome Therapeutics Market for Oral Therapeutics, 2022-2035 (USD Million)
- Figure 19.21 Microbiome Therapeutics Market for Rectal Therapeutics, 2022-2035 (USD Million)
- Figure 19.22 Microbiome Therapeutics Market: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
- Figure 19.23 Microbiome Therapeutics Market in North America, 2022-2035 (USD Million)
- Figure 19.24 Microbiome Therapeutics Market in Europe, 2022-2035 (USD Million)
- Figure 19.25 Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)
- Figure 19.26 Microbiome Therapeutics Market: Distribution by Leading Drug Developers, 2022-2035 (USD Million)
- Figure 19.27 Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, 2022-2035 (USD Million)
- Figure 19.28 CP101 (Finch Therapeutics): Target Patient Population
- Figure 19.29 CP101 (Finch Therapeutics): Sales Forecast, till 2035 (USD Million)
- Figure 19.30 IBP-9414 (Infant Bacterial Therapeutics): Target Patient Population
- Figure 19.31 IBP-9414 (Infant Bacterial Therapeutics): Sales Forecast, till 2035 (USD Million)
- Figure 19.32 MaaT013 (MaaT Pharma): Target Patient Population
- Figure 19.33 MaaT013 (MaaT Pharma): Sales Forecast, till 2035 (USD Million)
- Figure 19.34 Oxabact® (OxThera): Target Patient Population
- Figure 19.35 Oxabact® (OxThera): Sales Forecast, till 2035 (USD Million)
- Figure 19.36 RBX2660 (Rebiotix): Target Patient Population
- Figure 19.37 RBX2660 (Rebiotix): Sales Forecast, till 2035 (USD Million)
- Figure 19.38 SER-109 (Seres Therapeutics): Target Patient Population
- Figure 19.39 SER-109 (Seres Therapeutics): Sales Forecast, till 2035 (USD Million)
- Figure 20.1 Microbiome Diagnostics Market: Forecast Methodology and Key Assumptions
- Figure 20.2 Overall Microbiome Diagnostics Market, 2022-2035 (USD Million)
- Figure 20.3 Overall Microbiome Diagnostics Market, 2022-2035 (Units, Volume)
- Figure 20.4 Microbiome Diagnostics Market: Distribution by Target Indications, 2022-2035 (USD Million)
- Figure 20.5 Microbiome Diagnostics Market for Crohn’s Disease, 2022-2035 (USD Million)
- Figure 20.6 Microbiome Diagnostics Market for Colorectal Cancer, 2022-2035 (USD Million)
- Figure 20.7 Microbiome Diagnostics Market for Diabetes, 2022-2035 (USD Million)
- Figure 20.8 Microbiome Diagnostics Market for IBS, 2022-2035 (USD Million)
- Figure 20.9 Microbiome Diagnostics Market for Lung Cancer, 2022-2035 (USD Million)
- Figure 20.10 Microbiome Diagnostics Market for NASH, 2022-2035 (USD Million)
- Figure 20.11 Microbiome Diagnostics Market for Obesity, 2022-2035 (USD Million)
- Figure 20.12 Microbiome Diagnostics Market for Ulcerative Colitis, 2022-2035 (USD Million)
- Figure 20.13 Microbiome Diagnostics Market: Distribution by Target Indication, 2022-2035 (Units, Volume)
- Figure 20.14 Microbiome Diagnostics Market for Crohn’s Disease, 2022-2035 (Units, Volume)
- Figure 20.15 Microbiome Diagnostics Market for Colorectal Cancer, 2022-2035 (Units, Volume)
- Figure 20.16 Microbiome Diagnostics Market for Diabetes, 2022-2035 (Units, Volume)
- Figure 20.17 Microbiome Diagnostics Market for IBS, 2022-2035 (Units, Volume)
- Figure 20.18 Microbiome Diagnostics Market for Lung Cancer, 2022-2035 (Units, Volume)
- Figure 20.19 Microbiome Diagnostics Market for NASH, 2022-2035 (Units, Volume)
- Figure 20.20 Microbiome Diagnostics Market for Obesity, 2022-2035 (Units, Volume)
- Figure 20.21 Microbiome Diagnostics Market for Ulcerative Colitis, 2022-2035 (Units, Volume)
- Figure 20.22 Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2022-2035 (USD Million)
- Figure 20.23 Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2022-2035 (USD Million)
- Figure 20.24 Microbiome Diagnostics Market for Metabolic Disorders, 2022-2035 (USD Million)
- Figure 20.25 Microbiome Diagnostics Market for Oncology, 2022-2035 (USD Million)
- Figure 20.26 Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2022-2035 (Units, Volume)
- Figure 20.27 Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2022-2035 (Units, Volume)
- Figure 20.28 Microbiome Diagnostics Market for Metabolic Disorders, 2022-2035 (Units, Volume)
- Figure 20.29 Microbiome Diagnostics Market for Oncology, 2022-2035 (Units, Volume)
- Figure 20.30 Microbiome Diagnostics Market: Distribution by Supply Channel, 2022-2035 (USD Million)
- Figure 20.31 Microbiome Diagnostics Market for Hospital Pharmacies, 2022-2035 (USD Million)
- Figure 20.32 Microbiome Diagnostics Market for Retail Pharmacies, 2022-2035 (USD Million)
- Figure 20.33 Microbiome Diagnostics Market for Online Pharmacies, 2022-2035 (USD Million)
- Figure 20.34 Microbiome Diagnostics Market: Distribution by Supply Channel, 2022-2035 (Units, Volume)
- Figure 20.35 Microbiome Diagnostics Market for Hospital Pharmacies, 2022-2035 (Units, Volume)
- Figure 20.36 Microbiome Diagnostics Market for Retail Pharmacies, 2022-2035 (Units, Volume)
- Figure 20.37 Microbiome Diagnostics Market for Online Pharmacies, 2022-2035 (Units, Volume)
- Figure 20.38 Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
- Figure 20.39 Microbiome Diagnostics Market in North America, 2022-2035 (USD Million)
- Figure 20.40 Microbiome Diagnostics Market in Europe, 2022-2035 (USD Million)
- Figure 20.41 Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)
- Figure 20.42 Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2022-2035 (Units, Volume)
- Figure 20.43 Microbiome Diagnostics Market in North America, 2022-2035 (Units, Volume)
- Figure 20.44 Microbiome Diagnostics Market in Europe, 2022-2035 (Units, Volume)
- Figure 20.45 Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2022-2035 (Units, Volume)
- Figure 21.1 Fecal Microbiota Therapies: Forecast Methodology and Key Assumptions
- Figure 21.2 Overall FMT Market, 2022-2035 (USD Million)
- Figure 21.3 Overall FMT Market, 2022-2035 (Units, Volume)
- Figure 21.4 Overall Microbiome Market by Product Offerings: Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
- LIST OF TABLES
- Table 3.1 Types of Microbiota in the Gastrointestinal Tract
- Table 3.2 Common Instances of Misuse of Antibiotics
- Table 3.3 Impact of Antibiotics on Intestinal Microflora
- Table 3.4 List of Microorganisms Classified as Class I Carcinogens by the IARC
- Table 3.5 Relationship Between Microbiome and Disease Progression
- Table 3.6 Impact of Drug-Microbiome Interactions
- Table 3.7 List of Foods Containing Prebiotics
- Table 4.1 Microbiome Therapeutics: Clinical Pipeline
- Table 4.2 Clinical Phase Microbiome Therapeutics: Information on Type of Molecule and Route of Administration
- Table 4.3 Clinical Phase Microbiome Therapeutics: Additional Information
- Table 4.4 Microbiome Therapeutics: Preclinical Pipeline
- Table 4.5 Preclinical Phase Microbiome Therapeutics: Additional Information
- Table 4.6 Microbiome Therapeutics: List of Drug Developers
- Table 5.1 Microbiome Therapeutic Developers: Companies with Candidates in Highest Phase of Development
- Table 5.2 Finch Therapeutics: Microbiome-Based Product Portfolio
- Table 5.3 CP101: Current Status of Development
- Table 5.4 CP101: Clinical Studies
- Table 5.5 Finch Therapeutics: Recent Developments and Future Outlook
- Table 5.6 Infant Bacterial Therapeutics: Microbiome-Based Product Portfolio
- Table 5.7 IBP-9414: Current Status of Development
- Table 5.8 IBP-9414: Clinical Studies
- Table 5.9 Infant Bacterial Therapeutics: Recent Developments and Future Outlook
- Table 5.10 MaaT Pharma: Microbiome-Based Product Portfolio
- Table 5.11 MaaT013: Current Status of Development
- Table 5.12 MaaT013: Clinical Studies
- Table 5.13 MaaT Pharma: Recent Developments and Future Outlook
- Table 5.14 OxThera: Microbiome-Based Product Portfolio
- Table 5.15 Oxabact: Current Status of Development
- Table 5.16 Oxabact: Clinical Studies
- Table 5.17 OxThera: Recent Developments and Future Outlook
- Table 5.18 Rebiotix: Microbiome-Based Product Portfolio
- Table 5.19 RBX2660: Current Status of Development
- Table 5.20 RBX2660: Clinical Studies
- Table 5.21 Rebiotix: Recent Developments and Future Outlook
- Table 5.22 Seres Therapeutics: Microbiome-Based Product Portfolio
- Table 5.23 SER-109: Current Status of Development
- Table 5.24 SER-109: Clinical Studies
- Table 5.25 Seres Therapeutics: Recent Developments and Future Outlook
- Table 5.26 Microbiome Therapeutics Developers: Companies with Maximum Number of Therapeutic Programs
- Table 5.27 4D Pharma: Financial Information
- Table 5.28 4D Pharma: Recent Developments and Future Outlook
- Table 5.29 Biosortia Pharmaceuticals: Recent Developments and Future Outlook
- Table 5.30 Qu Biologics: Recent Developments and Future Outlook
- Table 5.31 Servatus: Recent Developments and Future Outlook
- Table 6.1 Microbiome Therapeutics: List of Clinical Trials
- Table 7.1 Microbiome Diagnostics and Screening / Profiling Tests: Marketed and Development Pipeline
- Table 7.2 Microbiome Diagnostics and Screening / Profiling Tests: List of Developers
- Table 8.1 Shoreline Biome: Company Overview
- Table 8.2 Shoreline Biome: Microbiome Test Portfolio
- Table 8.3 Shoreline Biome: Recent Developments and Future Outlook
- Table 8.4 DNA Genotek: Company Overview
- Table 8.5 DNA Genotek: Microbiome Test Portfolio
- Table 8.6 DNA Genotek: Recent Developments and Future Outlook
- Table 8.7 Invivo Healthcare: Company Overview
- Table 8.8 Invivo Healthcare: Microbiome Test Portfolio
- Table 8.9 Invivo Healthcare: Recent Developments and Future Outlook
- Table 8.10 GoodGut: Company Overview
- Table 8.11 GoodGut: Microbiome Test Portfolio
- Table 8.12 GoodGut: Recent Developments and Future Outlook
- Table 8.13 BiomeDx: Company Overview
- Table 8.14 BiomeDx: Microbiome Test Portfolio
- Table 8.15 BiomeDx: Recent Developments and Future Outlook
- Table 9.1 Comparison between Various Routes of Administration of FMT
- Table 9.2 FMT: Summary of Clinical Guidelines
- Table 9.3 FMT: Summary of Insurance Coverage Payer
- Table 9.4 FMT: Marketed and Development Pipeline
- Table 9.5 FMT: List of Developers
- Table 9.6 List of Stool Banks for FMT Development
- Table 9.7 Fecal Microbiota Transplant and Human Microbiome Transplant (HMT): Key Differences in Processing
- Table 9.8 Flora Medicine: Fecal Microbiota Transplant Treatment Cost
- Table 9.9 OpenBiome: Types of FMT Formulations
- Table 10.1 Fecal Microbiota Transplant: List of Registered Clinical Trials
- Table 14.1 Diabetes: Current Treatment Options
- Table 14.2 Diabetes: Side Effects of Current Treatment Options
- Table 14.3 Microbiome Therapeutics Candidates for Diabetes
- Table 14.4 Microbiome Therapeutics Candidates for Lactose Intolerance
- Table 14.5 Microbiome Therapeutics Candidates for NASH
- Table 14.6 Microbiome Therapeutics Candidates for Primary Hyperoxaluria
- Table 14.7 Obesity: Side Effects of Current Treatment Options
- Table 14.8 Microbiome Therapeutic Candidates for Obesity
- Table 14.9 Crohn’s Disease: Current Treatment Options
- Table 14.10 Crohn’s Disease: Side Effects of Current Treatment Options
- Table 14.11 Microbiome Therapeutics Candidates for Crohn’s Disease
- Table 14.12 IBS: Current Treatment Options
- Table 14.13 Microbiome Therapeutics Candidates for IBS
- Table 14.14 Ulcerative Colitis: Current Treatment Options
- Table 14.15 Ulcerative Colitis: Side Effects of Current Treatment Options
- Table 14.16 Microbiome Therapeutics Candidates for Ulcerative Colitis
- Table 14.17 Colorectal Cancer: Side Effects of Current Treatment Options
- Table 14.18 Microbiome Therapeutics Pipeline for Colorectal Cancer
- Table 14.19 Lung Cancer: Current Treatment Options
- Table 14.20 Lung Cancer: Side Effects of Current Treatment Options
- Table 14.21 Microbiome Therapeutics Candidates for Lung Cancer
- Table 14.22 Acne Vulgaris: Current Treatment Options
- Table 14.23 Acne Vulgaris: Side Effects of Current Treatment Options
- Table 14.24 Microbiome Therapeutics Candidates for Acne Vulgaris
- Table 14.25 CDI: Diagnostic Testing
- Table 14.26 CDI: Severity Scoring System and Treatment Options
- Table 14.27 CDI: Side Effects of Current Treatment Options
- Table 14.28 Microbiome Therapeutics Candidates for CDI
- Table 14.29 Bacterial Vaginosis: Current Treatment Options
- Table 14.30 Bacterial Vaginosis: Side Effects of Current Treatment Options
- Table 14.31 Microbiome Therapeutics Candidates for Bacterial Vaginosis
- Table 15.1 Microbiome Therapeutics and Diagnostics: Funding and Investments, Information on Funding Type, Year, Amount and Investor, 2017-2022 (till March)
- Table 15.2 Microbiome Therapeutics and Diagnostics: Funding and Investments, Information on Type of Product, Target Indication and Focus Area, 2017-2022 (till March)
- Table 15.3 Microbiome Therapeutics and Diagnostics: Funding and Investments, Information on Type of Investor and Location of Headquarters, 2017-2022 (till March)
- Table 16.1 Human Microbiome: List of Partnerships and Collaborations, 2017-2022 (till March)
- Table 17.1 Microbiome Contract Manufacturers: Information on Year of Establishment, Headquarters, Company Size, Accreditation Received and Scale of Operation
- Table 17.2 Microbiome Contract Manufacturers: Information on Type of Product Manufactured
- Table 17.2 Microbiome Contract Manufacturers: Information on Type of Formulation
- Table 17.6 Comparison of Key Factors for the Selection of Contract Service Providers: Harvey Ball Analysis
- Table 18.1 List of Companies Using Big Data for Microbiome Research
- Table 18.2 Human Longevity: Partnerships and Collaborations
- Table 18.3 Human Longevity: Venture Capital Funding
- Table 18.4 Resilient Biotics: Venture Capital Funding
- Table 19.1 List of Companies Engaged in the Development of Microbiome Products for Other Applications
- Table 19.2 Pipeline of Microbiome Based Consumer Products, Medical Foods and Supplements
- Table 23.1 S-Biomedic: Company Snapshot
- Table 23.2 Pendulum Therapeutics: Company Snapshot
- Table 23.3 Siolta Therapeutics: Company Snapshot
- Table 23.4 OpenBiome: Company Snapshot
- Table 23.5 Assembly Biosciences: Company Snapshot
- Table 23.6 List Biological Laboratories: Company Snapshot
- Table 23.7 Metabiomics: Company Snapshot
- Table 23.8 Microbiome Therapeutics: Company Snapshot
- Table 23.9 Universal Stabilization Technologies: Company Snapshot
- Table 23.10 BiomX: Company Snapshot
- Table 23.11 Da Volterra: Company Snapshot
- Table 23.12 Chung Mei Pharmaceutical: Company Snapshot
- Table 23.13 Pacific Northwest National Laboratories: Company Snapshot
- Table 23.14 Quorum Innovations: Company Snapshot
- Table 23.15 4D Pharma: Company Snapshot
- Table 24.1 Clinical Phase Microbiome Therapeutics: Distribution by Phase of Development
- Table 24.2 Clinical Phase Microbiome Therapeutics: Distribution by Type of Molecule
- Table 24.3 Clinical Phase Microbiome Therapeutics: Distribution by Phase of Development and Type of Molecule
- Table 24.4 Clinical Phase Microbiome Therapeutics: Distribution by Type of Biologic
- Table 24.5 Clinical Phase Microbiome Therapeutics: Distribution by Type of Product
- Table 24.6 Clinical Phase Microbiome Therapeutics: Distribution by Target Indication
- Table 24.7 Clinical Phase Microbiome Therapeutics: Distribution by Therapeutic Area
- Table 24.8 Clinical Phase Microbiome Therapeutics: Distribution by Route of Administration
- Table 24.9 Clinical Phase Microbiome Therapeutics: Distribution by Type of Formulation
- Table 24.10 Clinical Phase Microbiome Therapeutics: Distribution by Dose Frequency
- Table 24.11 Clinical Phase Microbiome Therapeutics: Distribution by Type of Therapy
- Table 24.12 Clinical Phase Microbiome Therapeutics: Distribution by Combination Drug
- Table 24.13 Preclinical Phase Microbiome Therapeutics: Distribution by Phase of Development
- Table 24.14 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Molecule
- Table 24.15 Preclinical Phase Microbiome Therapeutics: Distribution by Phase of Development and Type of Molecule
- Table 24.16 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Biologic
- Table 24.17 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Product
- Table 24.18 Preclinical Phase Microbiome Therapeutics: Distribution by Target Indication
- Table 24.19 Preclinical Phase Microbiome Therapeutics: Distribution by Therapeutic Area
- Table 24.20 Preclinical Phase Microbiome Therapeutics: Distribution by Route of Administration
- Table 24.21 Microbiome Therapeutic Developers: Distribution by Year of Establishment
- Table 24.22 Microbiome Therapeutic Developers: Distribution by Company Size
- Table 24.23 Microbiome Therapeutic Developers: Distribution by Location of Headquarters
- Table 24.24 Microbiome Therapeutic Developers: Distribution by Company Size and Location of Headquarters
- Table 24.25 Leading Drug Developers: Distribution by Number of Therapeutic Programs
- Table 24.26 Rebiotix: Financial Information, 2017-2021 (USD Million)
- Table 24.27 Seres Therapeutics: Financial Information, 2017-2021 (USD Million)
- Table 24.28 4D Pharma: Financial Information, 2017-2021 (USD Million)
- Table 24.29 Distribution by Trial Status
- Table 24.30 Distribution by Trial Registration Year
- Table 24.31 Distribution by Trial Registration Year and Type of Study
- Table 24.32 Distribution by Trial Phase and Trial Status
- Table 24.33 Year-wise Trend of Completed and Recruiting Trials
- Table 24.34 Distribution by Study Design
- Table 24.35 Distribution by Patient Enrollment
- Table 24.36 Distribution by Age Category
- Table 24.37 Distribution by Type of Sponsor / Collaborator
- Table 24.38 Most Active Industry Players: Distribution by Number of Registered Trials
- Table 24.39 Most Active Non-Industry Players: Distribution by Number of Registered Trials
- Table 24.40 Distribution by Trial Location
- Table 24.41 Distribution by Trial Status and Geography
- Table 24.42 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Stage of Development
- Table 24.43 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Test
- Table 24.44 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Stage of Development and Type of Test
- Table 24.45 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Sample Analyzed
- Table 24.46 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Screening Technique
- Table 24.47 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Target Indication
- Table 24.48 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Therapeutic Area
- Table 24.49 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Purpose of Test
- Table 24.50 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Year of Establishment
- Table 24.51 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Company Size
- Table 24.52 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Location of Headquarters
- Table 24.53 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Company Size and Location of Headquarters
- Table 24.54 Most Active Microbiome Test Providers: Distribution by Number of Microbiome Tests
- Table 24.55 Working Mechanism of a Microflora Refinement System
- Table 24.56 Fecal Microbiota Transplantation: Distribution by Application Area
- Table 24.57 Fecal Microbiota Transplantation: Distribution by Status of Development
- Table 24.58 Fecal Microbiota Transplantation: Distribution by Target Indication
- Table 24.59 Fecal Microbiota Transplantation: Distribution by Therapeutic Area
- Table 24.60 Fecal Microbiota Transplantation: Distribution by Route of Administration
- Table 24.61 Fecal Microbiota Transplantation Developers: Distribution by Year of Establishment
- Table 24.62 Fecal Microbiota Transplantation Developers: Distribution by Company Size
- Table 24.63 Fecal Microbiota Transplantation Developers: Distribution by Location of Headquarters
- Table 24.64 Fecal Microbiota Transplantation: Distribution by Trial Status
- Table 24.65 Fecal Microbiota Transplantation: Distribution by Trial Registration Year
- Table 24.66 Fecal Microbiota Transplantation: Distribution by Trial Registration Year and Type of Study
- Table 24.67 Fecal Microbiota Transplantation: Distribution by Trial Phase and Trial Status
- Table 24.68 Fecal Microbiota Transplantation: Year-wise Trend of Completed and Recruiting Trials
- Table 24.69 Fecal Microbiota Transplantation: Distribution by Study Design
- Table 24.70 Fecal Microbiota Transplantation: Distribution by Patient Enrollment
- Table 24.71 Fecal Microbiota Transplantation: Distribution by Age Category
- Table 24.72 Fecal Microbiota Transplantation: Distribution by Type of Sponsor / Collaborator
- Table 24.73 Most Active Industry Players: Distribution by Number of Registered Trials
- Table 24.74 Most Active Non-Industry Players: Distribution by Number of Registered Trials
- Table 24.75 Fecal Microbiota Transplantation: Distribution by Trial Location
- Table 24.76 Fecal Microbiota Transplantation: Distribution by Trial Status and Geography
- Table 24.77 Big Pharma Players: Analysis by Portfolio Diversity
- Table 24.78 Big Pharma Players: Distribution by Phase of Development
- Table 24.79 Big Pharma Players: Distribution by Type of Molecule
- Table 24.80 Big Pharma Players: Distribution by Type of Therapy
- Table 24.81 Big Pharma Players: Distribution by Diversity of Therapeutic Areas
- Table 24.82 Benchmarking of Start-ups: Distribution by Portfolio Diversity
- Table 24.83 Benchmarking of Start-ups: Distribution by Phase of Development
- Table 24.84 Benchmarking of Start-ups: Distribution by Diversity in Therapeutic Areas
- Table 24.85 Benchmarking of Start-ups: Distribution by Funding Amount
- Table 24.86 Benchmarking of Start-ups: Distribution by Number of Investors
- Table 24.87 Benchmarking of Start-ups: Distribution by Type of Funding
- Table 24.88 Benchmarking of Start-ups: Distribution by Partnership Activity
- Table 24.89 Benchmarking of Start-ups: Distribution by Patent Portfolio
- Table 24.90 Start-up Health Indexing: Roots Analysis Perspective
- Table 24.91 Diabetes: Diagnostic Limits for Plasma Glucose Levels
- Table 24.92 Non-Insulin Therapies for Diabetes
- Table 24.93 Weight Categories as per BMI Calculations
- Table 24.94 Causes of Obesity in Children
- Table 24.95 Obese Population: Distribution by Key Regions
- Table 24.96 Funding and Investment Analysis: Cumulative Distribution by Year of Investment, 2017-2022
- Table 24.97 Funding and Investment Analysis: Distribution by Type of Funding and Year of Investment, 2017-2022
- Table 24.98 Funding and Investment Analysis: Cumulative Distribution by Amount Invested, 2017-2022 (USD Million)
- Table 24.99 Funding and Investment Analysis: Year-Wise Distribution by Amount Invested and Type of Funding, 2017-2022 (USD Million)
- Table 24.100 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2017-2022
- Table 24.101 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2017-2022 (USD Million)
- Table 24.102 Funding and Investment Analysis: Summary of Amount Invested, 2017-2022 (USD Million)
- Table 24.103 Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Company, 2017-2022 (USD Million)
- Table 24.104 Funding and Investment Analysis: Distribution of the Total Amount Invested by Purpose of Funding, 2017-2022 (USD Million)
- Table 24.105 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Product, 2017-2022 (USD Million)
- Table 24.106 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Product and Funding Type, 2017-2022 (USD Million)
- Table 24.107 Funding and Investment Analysis: Distribution by Target Indication
- Table 24.108 Funding and Investment Analysis: Distribution of the Total Amount Invested by Target Indication, 2017-2022 (USD Million)
- Table 24.109 Funding and Investment Analysis: Distribution by Therapeutic Area
- Table 24.110 Funding and Investment Analysis: Distribution of the Total Amount Invested by Therapeutic Area, 2017-2022 (USD Million)
- Table 24.111 Funding and Investment Analysis: Distribution by Geography
- Table 24.112 Funding and Investment Analysis: Regional Distribution of Funding Instances
- Table 24.113 Most Active Players: Distribution by Number of Instances and Amount Invested, 2017-2022 (USD Million)
- Table 24.114 Most Active Investors: Distribution by Number of Instances
- Table 24.115 Funding and Investment Summary, 2017-2022 (USD Million)
- Table 24.116 Partnerships and Collaborations: Distribution of Year of Partnership
- Table 24.117 Partnerships and Collaborations: Distribution of Type of Partnership
- Table 24.118 Partnerships and Collaborations: Distribution of Year and Type of Partnership
- Table 24.119 Partnerships and Collaborations: Distribution of Type of Product
- Table 24.120 Partnerships and Collaborations: Distribution of Target Indication
- Table 24.121 Partnerships and Collaborations: Distribution of Therapeutic Area
- Table 24.122 Partnerships and Collaborations: Distribution of Type of Company
- Table 24.123 Partnerships and Collaborations: Distribution of Type of Partner
- Table 24.124 Most Active Players: Distribution by Number of Partnerships
- Table 24.125 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
- Table 24.126 Microbiome Contract Manufacturers: Distribution by Year of Establishment
- Table 24.127 Microbiome Contract Manufacturers: Distribution by Company Size
- Table 24.128 Microbiome Contract Manufacturers: Distribution by Location of Headquarters
- Table 24.129 Microbiome Contract Manufacturers: Distribution by Scale of Operation
- Table 24.130 Microbiome Contract Manufacturers: Distribution by Type of Product Manufactured
- Table 24.131 Microbiome Contract Manufacturers: Distribution by Type of Formulation
- Table 24.132 Microbiome Contract Manufacturers: Distribution by Scale of Operation and Type of Formulation
- Table 24.133 Microbiome Therapeutics Market: Forecast Methodology and Key Assumptions
- Table 24.134 Global Microbiome Therapeutics Market, 2022-2035 (USD Billion)
- Table 24.135 Microbiome Therapeutics Market: Distribution by Type of Product, 2022 and 2035
- Table 24.136 Microbiome Therapeutics Market for Probiotic Drugs, 2022-2035 (USD Million)
- Table 24.137 Microbiome Therapeutics Market for Other Drugs, 2022-2035 (USD Million)
- Table 24.138 Microbiome Therapeutics Market: Distribution by Type of Molecule, 2022 and 2035
- Table 24.139 Microbiome Therapeutics Market for Small Molecules, 2022-2035 (USD Million)
- Table 24.140 Microbiome Therapeutics Market for Biologics, 2022-2035 (USD Million)
- Table 24.141 Microbiome Therapeutics Market: Distribution by Target Disease Indication, 2022 and 2035
- Table 24.142 Microbiome Therapeutics Market for Graft Versus Host Disease, 2022-2035 (USD Million)
- Table 24.143 Microbiome Therapeutics Market for Necrotizing Enterocolitis, 2022-2035 (USD Million)
- Table 24.144 Microbiome Therapeutics Market for Primary Hyperoxaluria, 2022-2035 (USD Million)
- Table 24.145 Microbiome Therapeutics Market for Recurrent C. difficile Infection, 2022-2035 (USD Million)
- Table 24.146 Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2022 and 2035
- Table 24.147 Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, 2022-2035 (USD Million)
- Table 24.148 Microbiome Therapeutics Market for Infectious Diseases, 2022-2035 (USD Million)
- Table 24.149 Microbiome Therapeutics Market for Rare Disorders, 2022-2035 (USD Million)
- Table 24.150 Microbiome Therapeutics Market: Route of Administration, 2022-2035 (USD Million)
- Table 24.151 Microbiome Therapeutics Market for Oral Therapeutics, 2022-2035 (USD Million)
- Table 24.152 Microbiome Therapeutics Market for Rectal Therapeutics, 2022-2035 (USD Million)
- Table 24.153 Microbiome Therapeutics Market: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
- Table 24.154 Microbiome Therapeutics Market in North America, 2022-2035 (USD Million)
- Table 24.155 Microbiome Therapeutics Market in Europe, 2022-2035 (USD Million)
- Table 24.156 Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)
- Table 24.157 Microbiome Therapeutics Market: Distribution by Leading Drug Developers, 2022-2035 (USD Million)
- Table 24.158 Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, 2022-2035 (USD Million)
- Table 24.159 CP101 (Finch Therapeutics): Sales Forecast, till 2035 (USD Million)
- Table 24.160 IBP-9414 (Infant Bacterial Therapeutics): Sales Forecast, till 2035 (USD Million)
- Table 24.161 MaaT013 (MaaT Pharma): Sales Forecast, till 2035 (USD Million)
- Table 24.162 Oxabact® (OxThera): Sales Forecast, till 2035 (USD Million)
- Table 24.163 RBX2660 (Rebiotix): Sales Forecast, till 2035 (USD Million)
- Table 24.164 SER-109 (Seres Therapeutics): Sales Forecast, till 2035 (USD Million)
- Table 24.165 Microbiome Diagnostics Market: Forecast Methodology and Key Assumptions
- Table 24.166 Overall Microbiome Diagnostics Market, 2022-2035 (USD Million)
- Table 24.167 Overall Microbiome Diagnostics Market, 2022-2035 (Units, Volume)
- Table 24.168 Microbiome Diagnostics Market: Distribution by Target Indications, 2022-2035 (USD Million)
- Table 24.169 Microbiome Diagnostics Market for Crohn’s Disease, 2022-2035 (USD Million)
- Table 24.170 Microbiome Diagnostics Market for Colorectal Cancer, 2022-2035 (USD Million)
- Table 24.171 Microbiome Diagnostics Market for Diabetes, 2022-2035 (USD Million)
- Table 24.172 Microbiome Diagnostics Market for IBS, 2022-2035 (USD Million)
- Table 24.173 Microbiome Diagnostics Market for Lung Cancer, 2022-2035 (USD Million)
- Table 24.174 Microbiome Diagnostics Market for NASH, 2022-2035 (USD Million)
- Table 24.175 Microbiome Diagnostics Market for Obesity, 2022-2035 (USD Million)
- Table 24.176 Microbiome Diagnostics Market for Ulcerative Colitis, 2022-2035 (USD Million)
- Table 24.177 Microbiome Diagnostics Market: Distribution by Target Indication, 2022-2035 (Units, Volume)
- Table 24.178 Microbiome Diagnostics Market for Crohn’s Disease, 2022-2035 (Units, Volume)
- Table 24.179 Microbiome Diagnostics Market for Colorectal Cancer, 2022-2035 (Units, Volume)
- Table 24.180 Microbiome Diagnostics Market for Diabetes, 2022-2035 (Units, Volume)
- Table 24.181 Microbiome Diagnostics Market for IBS, 2022-2035 (Units, Volume)
- Table 24.182 Microbiome Diagnostics Market for Lung Cancer, 2022-2035 (Units, Volume)
- Table 24.183 Microbiome Diagnostics Market for NASH, 2022-2035 (Units, Volume)
- Table 24.184 Microbiome Diagnostics Market for Obesity, 2022-2035 (Units, Volume)
- Table 24.185 Microbiome Diagnostics Market for Ulcerative Colitis, 2022-2035 (Units, Volume)
- Table 24.186 Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2022-2035 (USD Million)
- Table 24.187 Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2022-2035 (USD Million)
- Table 24.188 Microbiome Diagnostics Market for Metabolic Disorders, 2022-2035 (USD Million)
- Table 24.189 Microbiome Diagnostics Market for Oncology, 2022-2035 (USD Million)
- Table 24.190 Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2022-2035 (Units, Volume)
- Table 24.191 Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2022-2035 (Units, Volume)
- Table 24.192 Microbiome Diagnostics Market for Metabolic Disorders, 2022-2035 (Units, Volume)
- Table 24.193 Microbiome Diagnostics Market for Oncology, 2022-2035 (Units, Volume)
- Table 24.194 Microbiome Diagnostics Market: Distribution by Supply Channel, 2022-2035 (USD Million)
- Table 24.195 Microbiome Diagnostics Market for Hospital Pharmacies, 2022-2035 (USD Million)
- Table 24.196 Microbiome Diagnostics Market for Retail Pharmacies, 2022-2035 (USD Million)
- Table 24.197 Microbiome Diagnostics Market for Online Pharmacies, 2022-2035 (USD Million)
- Table 24.198 Microbiome Diagnostics Market: Distribution by Supply Channel, 2022-2035 (Units, Volume)
- Table 24.199 Microbiome Diagnostics Market for Hospital Pharmacies, 2022-2035 (Units, Volume)
- Table 24.200 Microbiome Diagnostics Market for Retail Pharmacies, 2022-2035 (Units, Volume)
- Table 24.201 Microbiome Diagnostics Market for Online Pharmacies, 2022-2035 (Units, Volume)
- Table 24.202 Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
- Table 24.203 Microbiome Diagnostics Market in North America, 2022-2035 (USD Million)
- Table 24.204 Microbiome Diagnostics Market in Europe, 2022-2035 (USD Million)
- Table 24.205 Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)
- Table 24.206 Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2022-2035 (Units, Volume)
- Table 24.207 Microbiome Diagnostics Market in North America, 2022-2035 (Units, Volume)
- Table 24.208 Microbiome Diagnostics Market in Europe, 2022-2035 (Units, Volume)
- Table 24.209 Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2022-2035 (Units, Volume)
- Table 24.210 Fecal Microbiota Therapies: Forecast Methodology and Key Assumptions
- Table 24.211 Overall FMT Market, 2022-2035 (USD Million)
- Table 24.212 Overall FMT Market, 2022-2035 (Units, Volume)
- Table 24.213 Overall Microbiome Market by Product Offerings: Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
- LIST OF COMPANIES AND ORGANIZATIONS
- The following companies and organizations have been mentioned in the report.
- 1. 4D Pharma
- 2. 8VC
- 3. Aarhus University
- 4. Abdul Latif Jameel Health
- 5. Abstract Ventures
- 6. Acequia Capital
- 7. Adapsyn Bioscience
- 8. Adare Pharmaceuticals (acquired by THL and Frazier)
- 9. ADM Biopolis
- 10. AgroParisTech
- 11. Alexandria Venture Investments
- 12. Alveolus Bio (subsidiary of ResBiotic)
- 13. American Gastroenterological Association (AGA)
- 14. Anatara Life Sciences
- 15. AOBiome Therapeutics
- 16. Applied Biosystems
- 17. Ardigen
- 18. Arena Pharmaceuticals
- 19. Armata Pharmaceuticals
- 20. Arranta Bio
- 21. ARTIS Ventures
- 22. ARTPred
- 23. Asia Microbiota Bank
- 24. AstraZeneca
- 25. Atlas Biomed
- 26. Atmo Biosciences
- 27. Auggi (acquired by Seed Health)
- 28. Aumgene Biosciences
- 29. Auriga Partners
- 30. Austrian Research Promotion Agency (FFG)
- 31. Autism Impact Fund
- 32. Axial Biotherapeutics
- 33. Azenta Life Sciences
- 34. Azitra
- 35. Bacthera
- 36. Bayer
- 37. BBG Ventures
- 38. BD (Becton, Dickinson and Company)
- 39. Beiersdorf
- 40. Ben Franklin Technology Partners
- 41. Bill & Melinda Gates Foundation
- 42. BIOASTER
- 43. BioCat
- 44. Biocodex
- 45. BioCrossroads
- 46. BioGaia
- 47. Biohit
- 48. Biomathematica
- 49. Bio-Me
- 50. BiomeBank
- 51. Biomecite Diagnostics
- 52. Biomedical Advanced Research and Development Authority (BARDA)
- 53. BioMeD X
- 54. Biomica
- 55. Biomics
- 56. BiomX
- 57. Bios Partners
- 58. Biose
- 59. Biosortia Pharmaceuticals
- 60. BJP Laboratories
- 61. Blue Turtle Bio
- 62. Boehringer Ingelheim
- 63. Boston Children's Hospital
- 64. BoxGroup
- 65. Bpifrance
- 66. Bristol Myers Squibb
- 67. British Patient Capital
- 68. C.R. Bard (acquired by BD (Becton, Dickinson and Company))
- 69. C3J Therapeutics
- 70. Caelus Health
- 71. Cambridge Innovation Capital
- 72. Cambridge University Hospitals NHS Foundation Trust
- 73. Cancer Research UK
- 74. Candela Paramount
- 75. Cap Innov’Est
- 76. Capsugel (acquired by Lonza)
- 77. Carbiotix
- 78. cerascreen
- 79. Cerbios-Pharma
- 80. CHAIN Biotech
- 81. Chromaderm (acquired by DermBiont)
- 82. ChunLab
- 83. City of Hope
- 84. Civet BioSciences
- 85. Civilization Ventures
- 86. CJ Group
- 87. ClostraBio
- 88. Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)
- 89. Congruent Ventures
- 90. Connecticut Innovations
- 91. COPD Foundation
- 92. CoreBiome
- 93. Cornell University
- 94. Corundum Systems Biology
- 95. CosmosID
- 96. Crédit Mutuel Innovation
- 97. Crestovo
- 98. Crown Laboratories
- 99. Cykinso
- 100. Cytognos
- 101. Da Volterra
- 102. Dana-Farber Cancer Institute
- 103. Danone Manifesto Ventures
- 104. Darling Ventures
- 105. Debiopharm
- 106. DeepBiome Therapeutics
- 107. Department of Defense (DoD)
- 108. DermBiont
- 109. Diagnostic Solutions
- 110. Diversigen
- 111. DNA Genotek
- 112. DoctorsForMe (acquired by Human Longevity)
- 113. Domain Associates
- 114. DSM Venturing
- 115. Eagle Biosciences
- 116. Edico Genome (acquired by Illumina)
- 117. EirGenix
- 118. Elevate Ventures
- 119. Emerging Technologies Partners
- 120. Endoscopy Center of Red Bank
- 121. Enterin
- 122. Enterome
- 123. Equipo Ventures
- 124. Eurofins ADME BIOANALYSES
- 125. European Innovation Council (EIC)
- 126. European Union
- 127. Evelo Biosciences
- 128. Evologic Technologies
- 129. Evvy
- 130. Exeliom Biosciences
- 131. Ferring Pharmaceuticals
- 132. Filgen
- 133. Finch Therapeutics
- 134. Flora Medicine
- 135. Floragraph
- 136. Fonterra
- 137. Founders Fund
- 138. FUJIFILM Diosynth Biotechnologies
- 139. G9 Ventures
- 140. Galmed Pharmaceuticals
- 141. Genentech
- 142. General Catalyst
- 143. Genetic Analysis
- 144. Genetimes Technology
- 145. GENEWIZ
- 146. Genome & Company
- 147. Genopole
- 148. Genorama
- 149. Genosys
- 150. Genova Diagnostics
- 151. Gilead Sciences
- 152. Ginkgo Bioworks
- 153. GISEV
- 154. Global Brain
- 155. Goodgut
- 156. Groken Bioscience
- 157. GlaxoSmithKline
- 158. Gustave Roussy
- 159. Gusto Global
- 160. Hadasit Medical Research Services and Development
- 161. Harvard T.H. Chan School of Public Health
- 162. Harvard University
- 163. Heidelberg University
- 164. Hemi Ventures
- 165. Hercules Capital
- 166. Heritage Medical Systems
- 167. HIPRA
- 168. Holobiome
- 169. Hudson Institute of Medical Research
- 170. Human Longevity
- 171. Human Ventures
- 172. iCarbonX
- 173. Igen Biolab Group
- 174. Illumina
- 175. ImmuneBiotech
- 176. Immuron
- 177. inBiome
- 178. Indie Asset Partners
- 179. Infant Bacterial Therapeutics
- 180. Innovate UK
- 181. Inpac Probiotics
- 182. INRAE
- 183. Integrated BioBank of Luxembourg (IBBL)
- 184. Integrated Sciences
- 185. Invivo Healthcare
- 186. IP Group
- 187. Ixcela
- 188. Janssen
- 189. Jeneil Biotech
- 190. John Theurer Cancer Center
- 191. Johnson & Johnson
- 192. Joyance Partners
- 193. JSR
- 194. Juno Bio
- 195. K3 Ventures
- 196. Kairos Ventures
- 197. Kaleido Biosciences
- 198. Karolinska Institutet
- 199. KdT Ventures
- 200. Keiretsu Capital
- 201. Khosla Ventures
- 202. Leadiant Biosciences
- 203. Leiden University Medical Center
- 204. Leucine Rich Bio
- 205. Life Genomics
- 206. Life Sciences Fund Amsterdam (LSFA)
- 207. Life Sciences Partners
- 208. List Biological Laboratories
- 209. LIVEYOUNGER Institute
- 210. Locus Biosciences
- 211. Longevity Acquisition Corporation (a subsidiary of 4D Pharma)
- 212. Longwood Fund
- 213. LUCA Biologics
- 214. Luina Bio
- 215. Lundbeckfonden Foundation
- 216. Lunsford Capital
- 217. Luxia Scientific
- 218. MaaT Pharma
- 219. Macrogen
- 220. Maruho
- 221. Massachusetts General Hospital
- 222. MassChallenge Switzerland
- 223. MatriSys Bioscience
- 224. Mayo Clinic
- 225. MD Anderson Cancer Center
- 226. MegpPharm
- 227. Memorial Sloan Kettering Cancer Center
- 228. Merck
- 229. Metabiomics (a subsidiary of Prescient Medicine)
- 230. MetaboGen
- 231. MetaGenoPolis
- 232. Meteoric Biopharmaceuticals
- 233. Microba
- 234. Microbio
- 235. Microbiome Diagnostic Partners
- 236. Microbiome Research Centre
- 237. Microbiotica
- 238. Micronoma
- 239. Microviable Therapeutics
- 240. Mii Fund
- 241. Mirna Therapeutics
- 242. Mitchell Cancer Institute, University of South Alabama
- 243. MyBiotics
- 244. MyDiagnostics
- 245. MyMicroZoo
- 246. Naked Biome
- 247. Nascita Ventures
- 248. National Center for Advancing Translational Sciences
- 249. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- 250. National Institutes of Health (NIH)
- 251. National Instituteof Allergy and Infectious Diseases (NIAID)
- 252. National Research Council of Canada Industrial Research Assistance Program
- (NRC IRAP)
- 253. National Science Foundation (NSF)
- 254. Naval Medical Research Center
- 255. Nestlé Health Science
- 256. New Ventures
- 257. Next Act Fund
- 258. NextBiotics
- 259. NIZO
- 260. Notitia Biotechnologies
- 261. Novo Nordisk
- 262. Novozymes
- 263. NuBiyota
- 264. NYU Langone Health
- 265. OCA Ventures
- 266. Olive Tree Capital
- 267. Ombre
- 268. One Codex
- 269. OneVentures
- 270. OpenBiome
- 271. OptiBiotix Health
- 272. Oracle
- 273. Orion Fund
- 274. Osaka University Venture
- 275. OSbiome
- 276. Osel
- 277. Oxford Vacmedix
- 278. OxThera
- 279. Pacira Pharmaceuticals (formerly known as SkyePharma)
- 280. Palex Medical
- 281. Pangaea Ventures
- 282. Paris-Saclay University
- 283. Parkinson's UK
- 284. Pfizer
- 285. Phase Genomics
- 286. Phi Therapeutics
- 287. PHYZEN
- 288. Pivotal Life Sciences
- 289. PivotNorth Capital
- 290. Plug & Play Ventures
- 291. Polsky Center
- 292. Precigen ActoBio™
- 293. SOLVD Health (formerly known as Prescient Medicine Holdings)
- 294. Primer Capital
- 295. ProbioFerm
- 296. Probiotical
- 297. Probiotics Australia
- 298. ProdermIQ
- 299. Protexin
- 300. Psomagen
- 301. Qingdao Institute of Bioenergy and Bioprocess Technology
- 302. Qu Biologics
- 303. Quay Pharma
- 304. Queen Elizabeth Hospital
- 305. Quorum Innovations
- 306. Rambam Health Care Campus
- 307. Rebiotix
- 308. Relevance Ventures
- 309. Resilient Biotics
- 310. Resphera Biosciences
- 311. Rev1 Ventures
- 312. Rise Therapeutics
- 313. Roche
- 314. Rocky Mountain Analytical (RMA)
- 315. RondinX (acquired by BiomX)
- 316. Roswell Park Comprehensive Cancer Center
- 317. Sacco
- 318. S-Biomedic
- 319. Scanwell Health
- 320. SciBac
- 321. Sciencewerke
- 322. Scioto Biosciences
- 323. Second Genome
- 324. Seed Health
- 325. Seres Therapeutics
- 326. Servatus
- 327. Seventure Partners
- 328. SeylanMED (acquired by DermBiont)
- 329. SFA Therapeutics
- 330. Shanda Group
- 331. Shoreline Biome
- 332. Siolta Therapeutics
- 333. Skive Hospital
- 334. SNIPR Biome
- 335. Social Starts
- 336. Sofimac Innovation
- 337. SOSV
- 338. Spanish National Research Council (CSIC)
- 339. Standard Process
- 340. Stanford Cancer Institute
- 341. Stanford Health Care
- 342. Stanford University School of Medicine
- 343. Statens Serum Institut
- 344. Stellate Therapeutics
- 345. Stora Sköndal
- 346. Sun Genomics
- 347. Swiss Integrative Center for Human Health (SICHH)
- 348. Symberix
- 349. Symbiosis Pharma
- 350. Symbiotic Health
- 351. Symbiotix Biotherapies
- 352. Synlogic
- 353. Synthetic Biologics
- 354. Taiho Ventures
- 355. Takeda
- 356. Tech Coast Angels
- 357. Tencent Holdings
- 358. Thalys Medical Technology Group
- 359. The BioCollective
- 360. The Craftory
- 361. The Michael J. Fox Foundation for Parkinson's Research
- 362. The North Carolina Biotechnology Center
- 363. The Seerave Foundation
- 364. TNO
- 365. Toba Capital
- 366. Trail Mix Ventures (TMV)
- 367. Trayer Biotherapeutics
- 368. UAS Labs
- 369. uBiome
- 370. Unilever Ventures
- 371. Unique Biotech
- 372. University of Adelaide
- 373. University of Birmingham
- 374. University of California San Diego School of Medicine
- 375. University of Chicago
- 376. University of Minnesota
- 377. University of New South Wales
- 378. University of North Carolina
- 379. University of Nottingham
- 380. University of Queensland
- 381. University of Verona
- 382. Unpopular Ventures
- 383. UTokyo Innovation Platform
- 384. Vaiomer
- 385. Varinos
- 386. Vedanta Biosciences
- 387. Viking Global Investors
- 388. Viome
- 389. Virginia Commonwealth University
- 390. Virtue Group
- 391. Wacker Biotech
- 392. Walk-in-Lab
- 393. Washington Research Foundation
- 394. Washington University School of Medicine
- 395. WeGene
- 396. Wellington Partners
- 397. Wellmicro
- 398. Winclove Probiotics
- 399. Wing Venture Capital
- 400. WiSEED
- 401. Xbiome
- 402. Xycrobe Therapeutics
- 403. YSOPIA Bioscience
- 404. Zola Global Investors
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook